1
|
Louati S, Wozny AS, Malesys C, Daguenet E, Ladjohounlou R, Alphonse G, Tomasetto C, Magné N, Rodriguez-Lafrasse C. Differential Formation of Stress Granules in Radiosensitive and Radioresistant Head and Neck Squamous Cell Carcinoma Cells. Int J Radiat Oncol Biol Phys 2024; 118:485-497. [PMID: 37619790 DOI: 10.1016/j.ijrobp.2023.08.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 08/02/2023] [Accepted: 08/11/2023] [Indexed: 08/26/2023]
Abstract
PURPOSE Stress granules (SGs) are cytoplasmic aggregates in which mRNAs and specific proteins are trapped in response to a variety of damaging agents. They participate in the cellular defense mechanisms. Currently, their mechanism of formation in response to ionizing radiation and their role in tumor-cell radiosensitivity remain elusive. METHODS AND MATERIALS The kinetics of SG formation was investigated after the delivery of photon irradiation at different doses to head and neck squamous cell carcinoma cell lines with different radiosensitivities and the HeLa cervical cancer cell line (used as reference). In parallel, the response to a canonical inducer of SGs, sodium arsenite, was also studied. Immunolabeling of SG-specific proteins and mRNA fluorescence in situ hybridization enabled SG detection and quantification. Furthermore, a ribopuromycylation assay was used to assess the cell translational status. To determine whether reactive oxygen species were involved in SG formation, their scavenging or production was induced by pharmacologic pretreatment in both SCC61 and SQ20B cells. RESULTS Photon irradiation at different doses led to the formation of cytoplasmic foci that were positive for different SG markers. The presence of SGs gradually increased from 30 minutes to 2 hours postexposure in HeLa, SCC61, and Cal60 radiosensitive cells. In turn, the SQ20B and FaDu radioresistant cells did not form SGs. These results indicated a correlation between sensitivity to photon irradiation and SG formation. Moreover, SG formation was significantly reduced by reactive oxygen species scavenging using dimethyl sulfoxide in SCC61 cells, which supported their role in SG formation. However, a reciprocal experiment in SQ20B cells that depleted glutathione using buthionine sulfoximide did not restore SG formation in these cells. CONCLUSIONS SGs are formed in response to irradiation in radiosensitive, but not in radioresistant, head and neck squamous cell carcinoma cells. Interestingly, compared with sodium arsenite-induced SGs, photon-induced SGs exhibited a different morphology and cellular localization. Moreover, photon-induced SGs were not associated with the inhibition of translation; rather, they depended on oxidative stress.
Collapse
Affiliation(s)
- Safa Louati
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France; Department of Research and Teaching in Oncology, Hôpital Nord, Saint-Priest en Jarez, France
| | - Anne-Sophie Wozny
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France; Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Céline Malesys
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France
| | - Elisabeth Daguenet
- Department of Research and Teaching in Oncology, Hôpital Nord, Saint-Priest en Jarez, France
| | - Riad Ladjohounlou
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France
| | - Gersende Alphonse
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France; Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Catherine Tomasetto
- Institute of Genetic, Molecular and Cellular Biology, Université de Strasbourg, Illkirch, France
| | - Nicolas Magné
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France; Radiotherapy Department, Bergonié Institute, Bordeaux, France
| | - Claire Rodriguez-Lafrasse
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Université de Lyon, Lyon 1 University, Oullins, France; Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.
| |
Collapse
|
2
|
Grolleau E, Candiracci J, Lescuyer G, Barthelemy D, Benzerdjeb N, Haon C, Geiguer F, Raffin M, Hardat N, Balandier J, Rabeuf R, Chalabreysse L, Wozny AS, Rommelaere G, Rodriguez-Lafrasse C, Subtil F, Couraud S, Herzog M, Payen-Gay L. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules 2023; 13:1255. [PMID: 37627320 PMCID: PMC10452235 DOI: 10.3390/biom13081255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 08/04/2023] [Accepted: 08/07/2023] [Indexed: 08/27/2023] Open
Abstract
The molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also in the early detection of relapse. However, the clinical interpretation of a ctDNA negative result remains challenging. The characterization of circulating nucleosomes (carrying cell-free DNA) and associated epigenetic modifications (playing a key role in the tumorigenesis of different cancers) may provide useful information for patient management, by supporting the contributive value of ctDNA molecular profiling. Significantly elevated concentrations of H3K27Me3 nucleosomes were found in plasmas at the diagnosis, and during the follow-up, of NSCLC patients, compared to healthy donors (p-value < 0.0001). By combining the H3K27Me3 level and the ctDNA molecular profile, we found that 25.5% of the patients had H3K27Me3 levels above the cut off, and no somatic alteration was detected at diagnosis. This strongly supports the presence of non-mutated ctDNA in the corresponding plasma. During the patient follow-up, a high H3K27Me3-nucleosome level was found in 15.1% of the sample, despite no somatic mutations being detected, allowing the identification of disease progression from 43.1% to 58.2% over molecular profiling alone. Measuring H3K27Me3-nucleosome levels in combination with ctDNA molecular profiling may improve confidence in the negative molecular result for cfDNA in lung cancer at diagnosis, and may also be a promising biomarker for molecular residual disease (MRD) monitoring, during and/or after treatment.
Collapse
Affiliation(s)
- Emmanuel Grolleau
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Pulmonology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
| | - Julie Candiracci
- Belgian Volition SRL, Parc Scientifique Créalys, 5032 Isnes, Belgium
| | - Gaelle Lescuyer
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - David Barthelemy
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - Nazim Benzerdjeb
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Pathology Department, Claude Bernard University Lyon I, Hospices Civils de Lyon, 69677 Bron, France
| | - Christine Haon
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - Florence Geiguer
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - Margaux Raffin
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - Nathalie Hardat
- Belgian Volition SRL, Parc Scientifique Créalys, 5032 Isnes, Belgium
| | - Julie Balandier
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| | - Rémi Rabeuf
- Belgian Volition SRL, Parc Scientifique Créalys, 5032 Isnes, Belgium
| | - Lara Chalabreysse
- Pathology Department, Claude Bernard University Lyon I, Hospices Civils de Lyon, 69677 Bron, France
| | - Anne-Sophie Wozny
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
- Cellular and Molecular Radiobiology Laboratory UMR CNRS5822/IP2I, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
| | | | - Claire Rodriguez-Lafrasse
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
- Cellular and Molecular Radiobiology Laboratory UMR CNRS5822/IP2I, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
| | - Fabien Subtil
- Statistic Department, Hospices Civils de Lyon, 69008 Lyon, France
- LBBE, Claude Bernard University Lyon I, UMR 5558, CNRS, 69100 Villeurbanne, France
| | - Sébastien Couraud
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Pulmonology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
| | - Marielle Herzog
- Belgian Volition SRL, Parc Scientifique Créalys, 5032 Isnes, Belgium
| | - Lea Payen-Gay
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France
- Institute of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard University Lyon I, 69373 Lyon, France
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France
- Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France
| |
Collapse
|
3
|
Grolleau E, Candiracci J, Gauthier A, Lescuyer G, Barthelemy D, Haon C, Geiguer F, Raffin M, Hardat N, Balandier J, Rabeuf R, Wozny AS, Rommelaere G, Rodriguez-Lafrasse C, Subtil F, Couraud S, Herzog M, Payen-Gay L. Abstract 2163: Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-2163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Introduction: Treatment options of lung cancer (LC) comprise radiotherapy, and/or combined treatment approaches, including chemotherapy, immunotherapy and targeted therapies based on the tumoral molecular profile. Following curative-intent first-line therapies, clinical surveillance involves serial CT imaging. However, such surveillance can detect only macroscopic disease recurrence and is frequently inconclusive. NGS has been utilized to help identify and monitor treatment plans. Nucleosomes, complexes of DNA and histones proteins, are released during cell death into blood circulation. Trimethylation of lysine 27 on histone H3 (H3K27Me3), catalyzed by enhancer of zeste homolog 2 (EZH2), is a crucial epigenetic process in tumorigenesis. We investigated if H3K27Me3-nucleosome concentration could be a biomarker for molecular residual disease (MRD).
Patients and Methods: Plasmas were retrospectively collected from patients with advanced LC during treatment (CIRCAN’s cohort, n= 200) and from healthy donors (n=100). We carried out standard targeted NGS on paired plasmas. Samples were divided in two sub-groups based on genetical results: ctDNA negative (n=120) or positive (n=80) for presence of somatic alterations. Concentration of circulating H3K27Me3-nucleosome was measured using chemiluminescent Nu.Q® immunoassay (Belgian Volition SRL, Belgium).
Results: Significantly elevated concentrations of H3K27Me3-nucleosomes were found in LC plasmas during the follow-up of patients compared to healthy donors (median 14.9 ng/ml vs 6.15 ng/ml, respectively, p<0.001). In addition, H3K27Me3 levels is lower in the ctDNA-negative group compared to ctDNA-positive group (median 12.1 vs 24.8 ng/ml, respectively, p<0.001). At a clinical cut-off of 14 ng/ml, 62% of samples were positive for either H3K27Me3 or ctDNA, or for both, suggesting an active disease progression compared to only 40% detection using the NGS assay alone. 38% of the patients have low levels of H3K27Me3 and were ctDNA-negative strongly suggesting a therapeutic response under treatment.
Conclusions: High levels of Nu.Q® H3K27Me3 could allow physicians to detect MRD in LC patients following treatment with curative intent. This could be achieved by monitoring testing of patients at defined intervals of treatment and recovery, alongside imaging, to incorporate analyses of evolving molecular landscapes during treatment. In this setting, the H3K27Me3-nucleosome quantification, to complete the molecular exploration of cfDNA is highly encouraging, especially in advanced NSCLC, where re-tissue biopsies are impractical, expensive, and may cause undue harm. H3K27Me3-nucleosome quantification may also be useful in patient identification for specific treatments such as EZH2 inhibitor, but this requires investigation.
Citation Format: Emmanuel Grolleau, Julie Candiracci, Arnaud Gauthier, Gaelle Lescuyer, David Barthelemy, Christine Haon, Florence Geiguer, Margaux Raffin, Nathalie Hardat, Julie Balandier, Rémi Rabeuf, Anne-Sophie Wozny, Guillaume Rommelaere, Claire Rodriguez-Lafrasse, Fabien Subtil, Sébastien Couraud, Marielle Herzog, Lea Payen-Gay. Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2163.
Collapse
Affiliation(s)
| | | | | | | | | | - Christine Haon
- 1Centre Hospitalier Lyon Sud - HCL, Pierre Benite, France
| | | | - Margaux Raffin
- 1Centre Hospitalier Lyon Sud - HCL, Pierre Benite, France
| | | | | | | | | | | | | | - Fabien Subtil
- 1Centre Hospitalier Lyon Sud - HCL, Pierre Benite, France
| | | | | | - Lea Payen-Gay
- 1Centre Hospitalier Lyon Sud - HCL, Pierre Benite, France
| |
Collapse
|
4
|
Monneret D, Moreau A, Chirica C, Guergour D, Richet C, Desmurs L, Colognac S, Frugier A, Chévrier M, Marmontel O, Bonnefont-Rousselot D, Gonzalo P, Rodriguez-Lafrasse C, Cartier R. Non-linearity in lipase assays: A multicentric comparison on different analysers. Clin Biochem 2023; 114:63-66. [PMID: 36773631 DOI: 10.1016/j.clinbiochem.2023.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/21/2023] [Accepted: 02/08/2023] [Indexed: 02/13/2023]
Abstract
OBJECTIVES Non-linearity in lipase assays and the ensuing gaps in results distribution have been described on Roche analysers, but have yet to be studied on other analysers. DESIGN AND METHODS Eighteen lithium-heparinized plasma pools of lipase activities decreasing from 1700 to <4 U/L were prepared for multicentric evaluation on several analysers. Non-linearity was modelled as the difference between the polynomial regression of lipase activities depending on relative dilutions over the primary measuring range, and the linear regression of the same variables above the manufacturer's limit of linearity (MLL). Gaps in lipase distribution resulting from non-linearity were graphically evidenced through histograms. Upper limits of gaps were calculated, which are lipase activities where non-linearity biases no longer impact the diluted lipase results. RESULTS MLLs and lipase (U/L) calculated at MLL (%biases versus MLL) were respectively: 1200 and 1124 (-6.3%) on the Architect C16000 (Abbott); 300 and 248 (-17.3%) on the Cobas c503 (Roche); 1500 and 1458 (-2.8%) on the Dimension Vista (Siemens); and 700 and 659 (-5.9%) on the Atellica CH930 (Siemens). Using Sentinel Lipase reagents on Abbott analysers, these measurements were respectively: 300 and 294 (-2.0%) on the Architect C16000, and 300 and 298 (-0.7%) on the Alinity. Setting Randox Lipase reagents on the Alinity, MLL and lipase at MLL were 953 and 776 (-18.6%), respectively. CONCLUSIONS Considering the desirable (±14.2 %) and optimal (±7.1 %) allowable total error for lipase (EFLM/EuBIVAS), biases at manufacturer's limit of linearity were acceptable, except for Roche Cobas c503 method and Randox method on Abbott Alinity.
Collapse
Affiliation(s)
- Denis Monneret
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France.
| | - Amélie Moreau
- Service de Biochimie, CHU Saint-Etienne, F-42000 Saint-Etienne, France
| | - Carole Chirica
- Unité de Biochimie Immunoanalyse, Service de Biochimie Biologie Moléculaire et Toxicologie Environnementale, Institut de Biologie et Pathologie, CHU Grenoble, Université Grenoble Alpes, F-38000 Grenoble, France
| | - Dorra Guergour
- Unité de Biochimie Immunoanalyse, Service de Biochimie Biologie Moléculaire et Toxicologie Environnementale, Institut de Biologie et Pathologie, CHU Grenoble, Université Grenoble Alpes, F-38000 Grenoble, France
| | - Caroline Richet
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Laurent Desmurs
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Sylvie Colognac
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Audrey Frugier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Marc Chévrier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Oriane Marmontel
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Dominique Bonnefont-Rousselot
- Service de Biochimie Métabolique, AP-HP, Sorbonne Université, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, F-75000 Paris, France; Université Paris Cité, CNRS, INSERM, UTCBS, F-75006 Paris, France
| | - Philippe Gonzalo
- Service de Biochimie, CHU Saint-Etienne, F-42000 Saint-Etienne, France
| | - Claire Rodriguez-Lafrasse
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| | - Régine Cartier
- Service de Biochimie et Biologie Moléculaire, Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Hospices Civils de Lyon (HCL), F-69000 Lyon, France
| |
Collapse
|
5
|
Aloy MT, Sidi Boumedine J, Deville A, Kryza D, Gauthier A, Brichart-Vernos D, Ollier G, La Padula V, Lux F, Tillement O, Rodriguez-Lafrasse C, Janier M. Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma. Int J Nanomedicine 2022; 17:6655-6673. [PMID: 36582458 PMCID: PMC9793741 DOI: 10.2147/ijn.s390056] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 12/09/2022] [Indexed: 12/25/2022] Open
Abstract
Purpose Chondrosarcomas (CHSs), which represent 20% of primary bone tumors in adults, are mostly resistant to radio- and chemotherapy. It is therefore essential that new therapeutic approaches, targeted to the tumour, be developed to improve the prognosis of patients. The effectiveness, as a radiosensitizing agent, of gadolinium oxide nanoparticles (GdoNP, AGuIX®) nanoparticles in CHS was evaluated in vitro, in spheroid CHS models allowing to reproduce cell-cell extracellular matrix interactions, and, in vivo, in a nude mouse model with heterotopic tumour xenograft. Methods Spheroids from SW1353 and HEMC-SS cells were characterized by confocal microscopy with or without GdoNP treatment. Real-time microscopy enabled quantification of cell viability, cell migration and invasion. In vivo, the efficacy of the association of GdoNP combined with a single (4Gy) or fractionated (4x1Gy) irradiation was evaluated in HEMC-SS tumor-bearing mice by monitoring tumor growth, mouse survival and gene expression profile. Results The expression of proteoglycans in the extra-cellular matrix (ECM) of spheroids demonstrated the relevance of the 3-D model. The combination of GdoNP with single or fractionated irradiation increased the lethal effects of irradiation on 2-D- and 3-D-cultured cells. In vivo, a single or a fractionated dose of 4 Gy associated with IT or IV injection of GdoNP decreased tumor growth significantly. Only IT injection increased mice survival. Unexpectedly, the radiosensitizing effect of GdoNP was associated, in vitro, with a significant decrease in invasion-migration capacities and, in vivo, with the decreased expression of PTX3, a protein involved in the epithelial-to-mesenchymal transition process, suggesting a potential impact of GdoNP on metastasis formation. Conclusion These results provide the first proof of concept of the radiosensitizing effect of GdoNP in CHSs and opened the way for a multicentre, randomized Phase 2 trial evaluating the association of GdoNP with radiotherapy for the therapeutic management of patients with symptomatic inoperable musculoskeletal tumor lesions.
Collapse
Affiliation(s)
- Marie-Thérèse Aloy
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon, Lyon 1 University, Oullins, France
| | | | - Agathe Deville
- CNRS, LAGEPP, UMR5007, IMTHERNAT, Lyon 1 University, Hospital Edouard Herriot, Lyon, France,Department of Nuclear Medicine, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - David Kryza
- CNRS, LAGEPP, UMR5007, IMTHERNAT, Lyon 1 University, Hospital Edouard Herriot, Lyon, France
| | - Arnaud Gauthier
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon, Lyon 1 University, Oullins, France,Department of Biochemistry and Molecular Biology, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Delphine Brichart-Vernos
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon, Lyon 1 University, Oullins, France,Light Matter Institut UMR CNRS 5306, Lyon 1 University, Villeurbanne, France
| | - Grégoire Ollier
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon, Lyon 1 University, Oullins, France
| | - Veronica La Padula
- Light Matter Institut UMR CNRS 5306, Lyon 1 University, Villeurbanne, France
| | - François Lux
- Light Matter Institut UMR CNRS 5306, Lyon 1 University, Villeurbanne, France
| | - Olivier Tillement
- Light Matter Institut UMR CNRS 5306, Lyon 1 University, Villeurbanne, France
| | - Claire Rodriguez-Lafrasse
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon, Lyon 1 University, Oullins, France,Department of Biochemistry and Molecular Biology, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Marc Janier
- CNRS, LAGEPP, UMR5007, IMTHERNAT, Lyon 1 University, Hospital Edouard Herriot, Lyon, France,Department of Nuclear Medicine, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France,Correspondence: Marc Janier, Department of Nuclear Medicine, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, 69634, France, Tel +33472356999, Fax +33472357345, Email
| |
Collapse
|
6
|
Sauvaigo S, Muggiolu G, Libert S, Treillard B, Alphonse G, Righini CA, Ceruse P, Philouze P, Rodriguez-Lafrasse C. Abstract 3493: Comprehensive analysis of the DNA repair enzyme signature in tumor and blood cells from head and neck cancer patients and correlation with clinical data from a 18-months follow-up study. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer worldwide. It is often associated with a history of smoking/alcohol consumption or exposure to the human papilloma virus (HPV). Beyond surgery, treatment usually includes DNA damaging treatments i.e. cisplatin/5FU combined or not with radiation therapy. Treatment failure rates are still high due to intrinsic and acquired mechanisms of resistance, largely involving DNA repair mechanisms. Here we precisely examined the main DNA repair mechanisms susceptible to drive tumor progression and resistance to treatment, using a miniaturized comprehensive functional approach on biochip. Enzymatic DNA repair profiles were compared for lymphocytes and tumor biopsies taken before treatment from 38 patients in a prospective clinical study. We simultaneously investigated double strand break repair pathways (HR, NHEJ, SSA, alt-EJ), excision/synthesis repair mechanisms (BER, NER, ICLR) and several glycosylases/AP endonuclease activities, using lysates prepared from the samples. Results were correlated with physiologic and lifestyle/risk factors, TNM tumor classification, treatment-induced adverse effects, and disease progression or death at 18 months. Analysis of blood cells and biopsies provided different and complementary information. Indeed, the prediction of treatment-induced severe toxicity was effective on blood cells. Several risk factors significantly affected specific repair activities of tumor cells. HPV positive and negative tumors displayed distinct DNA repair profiles and, cancer progression and tumor staging correlated with deregulated repair activities in tumors. Interestingly, the most affected DNA repair activities concerned double strand break repair, repair of cisplatin adducts, and repair of oxidative damage. This accurate DNA repair profiling represents an innovative strategy to reveal tumor diversity and better understand the impact of risk factors. It improved our understanding of the role of DNA repair in the development and progression of cancer. In addition, the use of a panel of DNA repair-based enzymatic biomarkers is more accurate than the single parameter approach in stratifying patients into different groups, thus allowing for more effective therapeutic strategies.
Citation Format: Sylvie Sauvaigo, Giovanna Muggiolu, Sarah Libert, Bertrand Treillard, Gersende Alphonse, Christian A. Righini, Philippe Ceruse, Pierre Philouze, Claire Rodriguez-Lafrasse. Comprehensive analysis of the DNA repair enzyme signature in tumor and blood cells from head and neck cancer patients and correlation with clinical data from a 18-months follow-up study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3493.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Philippe Ceruse
- 4Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France
| | - Pierre Philouze
- 4Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France
| | | |
Collapse
|
7
|
Rocchi P, Brichart-Vernos D, Lux F, Morfin I, David L, Rodriguez-Lafrasse C, Tillement O. A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers. Pharmaceutics 2022; 14:pharmaceutics14040814. [PMID: 35456648 PMCID: PMC9024746 DOI: 10.3390/pharmaceutics14040814] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 03/23/2022] [Accepted: 03/29/2022] [Indexed: 12/29/2022] Open
Abstract
An emerging target to overcome cancer resistance to treatments is copper, which is upregulated in a wide variety of tumors and may be associated with cancer progression and metastases. The aim of this study was to develop a multimodal ultrasmall nanoparticle, CuPRiX, based on the clinical AGuIX nanoparticle made of the polysiloxane matrix on which gadolinium chelates are grafted. Such hybrid nanoparticles allow: (i) a localized depletion of copper in tumors to prevent tumor cell dissemination and metastasis formation and (ii) an increased sensitivity of the tumor to radiotherapy (RT) due to the presence of high Z gadolinium (Gd) atoms. CuPRiX nanoparticles are obtained by controlled acidification of AGuIX nanoparticles. They were evaluated in vitro on two cancer cell lines (lung and head and neck) using the scratch-wound assay and clonogenic cell survival assay. They were able to reduce cell migration and invasion and displayed radiosensitizing properties.
Collapse
Affiliation(s)
- Paul Rocchi
- Institut Lumière Matière, Université Claude Bernard Lyon 1CNRS UMR 5306, 69622 Villeurbanne, France; (P.R.); (D.B.-V.); (O.T.)
- NH TherAguix SA, 38240 Meylan, France
| | - Delphine Brichart-Vernos
- Institut Lumière Matière, Université Claude Bernard Lyon 1CNRS UMR 5306, 69622 Villeurbanne, France; (P.R.); (D.B.-V.); (O.T.)
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Univ. Lyon, Lyon 1 University, 69921 Oullins, France;
| | - François Lux
- Institut Lumière Matière, Université Claude Bernard Lyon 1CNRS UMR 5306, 69622 Villeurbanne, France; (P.R.); (D.B.-V.); (O.T.)
- Institut Universitaire de France (IUF), 75000 Paris, France
- Correspondence: ; Tel.: +33-4-72-43-12-00
| | - Isabelle Morfin
- LiPhy, Université Grenoble Alpes, CNRS, UMR UMR5588, 38401 Grenoble, France;
| | - Laurent David
- Ingénierie des Matériaux Polymères, Université de Lyon, Université Claude Bernard Lyon 1, Université Jean Monet, Institut National des Sciences Appliquées de Lyon, CNRS, UMR 5223, 15, bd A. Latarjet, 69622 Villeurbanne, France;
| | - Claire Rodriguez-Lafrasse
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Univ. Lyon, Lyon 1 University, 69921 Oullins, France;
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils of Lyon, 69310 Pierre-Bénite, France
| | - Olivier Tillement
- Institut Lumière Matière, Université Claude Bernard Lyon 1CNRS UMR 5306, 69622 Villeurbanne, France; (P.R.); (D.B.-V.); (O.T.)
| |
Collapse
|
8
|
Gauthier A, Philouze P, Lauret A, Alphonse G, Malesys C, Ardail D, Payen L, Céruse P, Wozny AS, Rodriguez-Lafrasse C. Circulating Tumor Cell Detection during Neoadjuvant Chemotherapy to Predict Early Response in Locally Advanced Oropharyngeal Cancers: A Prospective Pilot Study. J Pers Med 2022; 12:jpm12030445. [PMID: 35330447 PMCID: PMC8950569 DOI: 10.3390/jpm12030445] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 03/07/2022] [Accepted: 03/08/2022] [Indexed: 02/04/2023] Open
Abstract
Patients with locally advanced oropharyngeal carcinoma treated with neoadjuvant chemotherapy are reassessed both radiologically and clinically to adapt their treatment after the first cycle. However, some responders show early tumor progression after adjuvant radiotherapy. This cohort study evaluated circulating tumor cells (CTCs) from a population of locally advanced oropharyngeal carcinoma patients treated with docetaxel, cisplatin, and 5-fluorouracil (DCF) induction chemotherapy or DCF with a modified dose and fractioned administration. The counts and phenotypes of CTCs were assessed at baseline and at day 21 of treatment, after isolation using the RosetteSepTM technique based on negative enrichment. At baseline, 6 out of 21 patients had CTCs (28.6%). On day 21, 5 out of 11 patients had CTCs (41.6%). There was no significant difference in the overall and progression-free survival between patients with or without CTCs at baseline (p = 0.44 and 0.78) or day 21 (p = 0.88 and 0.5). Out of the 11 patients tested at day 21, 4 had a positive variation of CTCs (33%). Patients with a positive variation of CTCs display a lower overall survival. Our findings suggest that the variation in the number of CTCs would be a better guide to the management of treatment, with possible early changes in treatment strategy.
Collapse
Affiliation(s)
- Arnaud Gauthier
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
| | - Pierre Philouze
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of OtoRhinoLaryngology Head and Neck Surgery, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France
| | - Alexandra Lauret
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
| | - Gersende Alphonse
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
| | - Céline Malesys
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
| | - Dominique Ardail
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
| | - Léa Payen
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
| | - Philippe Céruse
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of OtoRhinoLaryngology Head and Neck Surgery, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France
| | - Anne-Sophie Wozny
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
| | - Claire Rodriguez-Lafrasse
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France; (A.G.); (P.P.); (A.L.); (G.A.); (C.M.); (D.A.); (P.C.); (A.-S.W.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France;
- Correspondence: ; Tel.: +33-4-26-23-59-65
| |
Collapse
|
9
|
Soumboundou M, Dossou J, Kalaga Y, Nkengurutse I, Faye I, Guingani A, Gadji M, Yameogo KJ, Zongo H, Mbaye G, Dem A, Diarra M, Adjibade R, Djebou C, Junker S, Oudrhiri N, Hempel WM, Dieterlen A, Jeandidier E, Carde P, El Maalouf E, Colicchio B, Bennaceur-Griscelli A, Fenech M, Voisin P, Rodriguez-Lafrasse C, M'Kacher R. Is Response to Genotoxic Stress Similar in Populations of African and European Ancestry? A Study of Dose-Response After in vitro Irradiation. Front Genet 2021; 12:657999. [PMID: 34868192 PMCID: PMC8632650 DOI: 10.3389/fgene.2021.657999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Accepted: 05/13/2021] [Indexed: 11/17/2022] Open
Abstract
Background: Exposure to genotoxic stress such as radiation is an important public health issue affecting a large population. The necessity of analyzing cytogenetic effects of such exposure is related to the need to estimate the associated risk. Cytogenetic biological dosimetry is based on the relationship between the absorbed dose and the frequency of scored chromosomal aberrations. The influence of confounding factors on radiation response is a topical issue. The role of ethnicity is unclear. Here, we compared the dose-response curves obtained after irradiation of circulating lymphocytes from healthy donors of African and European ancestry. Materials and Methods: Blood samples from six Africans living in Africa, five Africans living in Europe, and five Caucasians living in Europe were exposed to various doses (0–4 Gy) of X-rays at a dose-rate of 0.1 Gy/min using an X-RAD320 irradiator. A validated cohort composed of 14 healthy Africans living in three African countries was included and blood samples were irradiated using the same protocols. Blood lymphocytes were cultured for 48 h and chromosomal aberrations scored during the first mitosis by telomere and centromere staining. The distribution of dicentric chromosomes was determined and the Kruskal-Wallis test was used to compare the dose-response curves of the two populations. Results: No spontaneous dicentric chromosomes were detected in African donors, thus establishing a very low background of unstable chromosomal aberrations relative to the European population. There was a significant difference in the dose response curves between native African and European donors. At 4 Gy, African donors showed a significantly lower frequency of dicentric chromosomes (p = 8.65 10–17), centric rings (p = 4.0310–14), and resulting double-strand-breaks (DSB) (p = 1.32 10–18) than European donors. In addition, a significant difference was found between African donors living in Europe and Africans living in Africa. Conclusion: This is the first study to demonstrate the important role of ethnic and environmental factors that may epigenetically influence the response to irradiation. It will be necessary to establish country-of-origen-specific dose response curves to practice precise and adequate biological dosimetry. This work opens new perspective for the comparison of treatments based on genotoxic agents, such as irradiation.
Collapse
Affiliation(s)
| | - Julien Dossou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Yossef Kalaga
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | | | - Albert Guingani
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | - Koudbi J Yameogo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Henri Zongo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Gora Mbaye
- Laboratoire Biophysique UFR-Santé, Dakar, Senegal
| | | | | | - Rached Adjibade
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Catherine Djebou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Noufissa Oudrhiri
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | | | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Patrice Carde
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Annelise Bennaceur-Griscelli
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | - Michael Fenech
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.,Genome Health Foundation, North Brighton, SA, Australia.,Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | | | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, UMR CNRS5822/IN2P3, IPNL, PRISME, Oullins, France
| | | |
Collapse
|
10
|
Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy. Med Sci Monit 2021; 27:e934116. [PMID: 34728593 PMCID: PMC8573967 DOI: 10.12659/msm.934116] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Hypoxia involves neoplastic cells. Unlike normal tissue, solid tumors are composed of aberrant vasculature, leading to a hypoxic microenvironment. Hypoxia is also known to be involved in both metastasis initiation and therapy resistance. Radiotherapy is the appropriate treatment in about half of all cancers, but loco-regional control failure and a disease recurrence often occur due to clinical radioresistance. Hypoxia induces radioresistance through a number of molecular pathways, and numerous strategies have been developed to overcome this. Nevertheless, these strategies have resulted in disappointing results, including adverse effects and limited efficacy. Additional clinical studies are needed to achieve a better understanding of the complex hypoxia pathways. This review presents an update on the mechanisms of hypoxia in radioresistance in solid tumors and the potential therapeutic solutions.
Collapse
Affiliation(s)
- Wafa Bouleftour
- Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France
| | - Elise Rowinski
- Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France
| | - Safa Louati
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, France.,Hospices Civils de Lyon, Lyon, France
| | - Sandrine Sotton
- Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France
| | - Anne-Sophie Wozny
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, France.,Hospices Civils de Lyon, Lyon, France
| | - Pablo Moreno-Acosta
- Research Group in Cancer Biology, National Cancer Institute, Bogotá, Colombia
| | - Benoite Mery
- Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France
| | - Claire Rodriguez-Lafrasse
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, France.,Hospices Civils de Lyon, Lyon, France
| | - Nicolas Magne
- Radiotherapy Department, Lucien Neuwirth Cancerology Institute, Saint Priest en Jarez, France.,Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, France.,Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
11
|
Averbeck D, Rodriguez-Lafrasse C. Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts. Int J Mol Sci 2021; 22:ijms222011047. [PMID: 34681703 PMCID: PMC8541263 DOI: 10.3390/ijms222011047] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 09/24/2021] [Accepted: 10/08/2021] [Indexed: 12/15/2022] Open
Abstract
Until recently, radiation effects have been considered to be mainly due to nuclear DNA damage and their management by repair mechanisms. However, molecular biology studies reveal that the outcomes of exposures to ionizing radiation (IR) highly depend on activation and regulation through other molecular components of organelles that determine cell survival and proliferation capacities. As typical epigenetic-regulated organelles and central power stations of cells, mitochondria play an important pivotal role in those responses. They direct cellular metabolism, energy supply and homeostasis as well as radiation-induced signaling, cell death, and immunological responses. This review is focused on how energy, dose and quality of IR affect mitochondria-dependent epigenetic and functional control at the cellular and tissue level. Low-dose radiation effects on mitochondria appear to be associated with epigenetic and non-targeted effects involved in genomic instability and adaptive responses, whereas high-dose radiation effects (>1 Gy) concern therapeutic effects of radiation and long-term outcomes involving mitochondria-mediated innate and adaptive immune responses. Both effects depend on radiation quality. For example, the increased efficacy of high linear energy transfer particle radiotherapy, e.g., C-ion radiotherapy, relies on the reduction of anastasis, enhanced mitochondria-mediated apoptosis and immunogenic (antitumor) responses.
Collapse
Affiliation(s)
- Dietrich Averbeck
- Laboratory of Cellular and Molecular Radiobiology, PRISME, UMR CNRS 5822/IN2P3, IP2I, Lyon-Sud Medical School, University Lyon 1, 69921 Oullins, France;
- Correspondence:
| | - Claire Rodriguez-Lafrasse
- Laboratory of Cellular and Molecular Radiobiology, PRISME, UMR CNRS 5822/IN2P3, IP2I, Lyon-Sud Medical School, University Lyon 1, 69921 Oullins, France;
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
| |
Collapse
|
12
|
Muggiolu G, Libert S, Treillard B, Alfonse G, Philouze P, Rodriguez-Lafrasse C, Lauret A, Ceruse P, Righini C, Sauvaigo S. PO-1929 Identification of DNA repair-based biomarkers related to treatment outcome in head and neck cancers. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08380-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Wozny AS, Gauthier A, Alphonse G, Malésys C, Varoclier V, Beuve M, Brichart-Vernos D, Magné N, Vial N, Ardail D, Nakajima T, Rodriguez-Lafrasse C. Involvement of HIF-1α in the Detection, Signaling, and Repair of DNA Double-Strand Breaks after Photon and Carbon-Ion Irradiation. Cancers (Basel) 2021; 13:cancers13153833. [PMID: 34359734 PMCID: PMC8345054 DOI: 10.3390/cancers13153833] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 07/22/2021] [Accepted: 07/26/2021] [Indexed: 01/31/2023] Open
Abstract
Simple Summary Hypoxia-Inducible Factor 1α (HIF-1α), the main regulator of the oxygen homeostasis, promotes cancer cell survival through proliferation, angiogenesis, metastasis and radioresistance. Previously, our group demonstrated that silencing HIF-1α under hypoxia leads to a substantial radiosensitization of Head-and-Neck Squamous Cell Carcinoma (HNSCC) cells after both photons and carbon-ions, probably resulting from an accumulation of deleterious complex DNA damage. In this study, we aimed at determining the potential role of HIF-1α in the detection, signaling, and repair of DNA Double-Strand-Breaks (DSBs) in response to both irradiations, under hypoxia, in two HNSCC cell lines and their subpopulations of Cancer-Stem Cells (CSCs). Silencing HIF-1α under hypoxia led us to demonstrate the involvement of this transcriptional regulator in DSB repair in non-CSCS and CSC, thus highlighting its targeting together with radiation as a promising therapeutic strategy against radioresistant tumor cells in hypoxic niches. Abstract Hypoxia-Inducible Factor 1α (HIF-1α), which promotes cancer cell survival, is the main regulator of oxygen homeostasis. Hypoxia combined with photon and carbon ion irradiation (C-ions) stabilizes HIF-1α. Silencing HIF-1α under hypoxia leads to substantial radiosensitization of Head-and-Neck Squamous Cell Carcinoma (HNSCC) cells after both photons and C-ions. Thus, this study aimed to clarify a potential involvement of HIF-1α in the detection, signaling, and repair of DNA Double-Strand-Breaks (DSBs) in response to both irradiations, in two HNSCC cell lines and their subpopulations of Cancer-Stem Cells (CSCs). After confirming the nucleoshuttling of HIF-1α in response to both exposure under hypoxia, we showed that silencing HIF-1α in non-CSCs and CSCs decreased the initiation of the DSB detection (P-ATM), and increased the residual phosphorylated H2AX (γH2AX) foci. While HIF-1α silencing did not modulate 53BP1 expression, P-DNA-PKcs (NHEJ-c) and RAD51 (HR) signals decreased. Altogether, our experiments demonstrate the involvement of HIF-1α in the detection and signaling of DSBs, but also in the main repair pathways (NHEJ-c and HR), without favoring one of them. Combining HIF-1α silencing with both types of radiation could therefore present a potential therapeutic benefit of targeting CSCs mostly present in tumor hypoxic niches.
Collapse
Affiliation(s)
- Anne-Sophie Wozny
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
| | - Arnaud Gauthier
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
| | - Gersende Alphonse
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
| | - Céline Malésys
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
| | - Virginie Varoclier
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
| | - Michael Beuve
- Univ Lyon, Lyon 1 University, UMR CNRS5822/IP2I, 69100 Villeurbanne, France;
| | - Delphine Brichart-Vernos
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
| | - Nicolas Magné
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Radiotherapy, Institute of Cancerology Lucien Neuwirth, 42270 Saint-Priest-en-Jarez, France
| | - Nicolas Vial
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Radiotherapy, Institute of Cancerology Lucien Neuwirth, 42270 Saint-Priest-en-Jarez, France
| | - Dominique Ardail
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
| | - Tetsuo Nakajima
- Department of Radiation Effects Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan;
| | - Claire Rodriguez-Lafrasse
- Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Univ Lyon, Lyon 1 University, 69921 Oullins, France; (A.-S.W.); (A.G.); (G.A.); (C.M.); (V.V.); (D.B.-V.); (N.M.); (N.V.); (D.A.)
- Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
- Correspondence: ; Tel.: +33-426-235-965
| |
Collapse
|
14
|
Sauvaigo S, Muggiolu G, Libert S, Daguenet E, Rodriguez-Lafrasse C, Maillet T, Magné N. Abstract 681: Prospective study for the identification of DNA repair radiotoxicity biomarkers in breast and prostate cancer patients: Cohort description and descriptive statistics. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Radiotherapy (RT) can induce with short-term (acute) and long term toxicity. Although acute toxicity is generally well tolerated, long term toxicity might be irreversible and progressive over time. RT induces damage in healthy tissue, triggers inflammation and bystander effects in non-irradiated cells. The toxicity is dependent on many variables and precise knowledge on the responsible mechanisms is still lacking.
Purpose: DNA damage, DNA repair and inflammation are known to interplay. Because of the specific involvement of Base Excision Repair (BER) in Reactive Oxygen and Nitrogen species (RONs)-induced lesions and inflammation, we monitored BER activities in patients receiving radiotherapy to investigate glycosylase/AP endonucleases activities as potential biomarkers of radiotoxicity. First, impact of gender, age, concomitant treatment, body mass index (BMI), smoking and alcohol consumption, on basal repair levels, and radiation-induced repair activities were evaluated. Methods: About 220 patients suffering from non-metastatic breast or prostate cancer and treated by radiotherapy (RT) were enrolled by Institut de Cancérologie Lucien Neuwirth. 8 mL of blood was collected prior to RT, 24h after the first radiation dose and before the 6th radiation dose. We then used the Glyco-SPOT assay to quantify BER activities, and nucleases level in lysates prepared from the patients' lymphocytes. Patients were followed-up for at least 6 months. Clinical and toxicity data were collected. All adverse events (AE; acute, sub-acute and late) were scored according to Common Terminology Criteria for Adverse Events.
Results: Due to differences in the BER profile between prostate and breast cancer patients, the two groups were analyzed separately. We provide a descriptive overview of recorded AE for each group, according to time period. Some significant specific changes in BER activities where associated with smoking, alcohol consumption, BMI, treatment type and age.
Conclusion: Known risk factors significantly affected some BER activities. Males and females should be considered independently for radiotoxicity biomarkers identification using glycosylase/AP endonuclease/nucleases related biomarkers. The identification of possible confounding factors is a prerequisite to any selection of radiotoxicity biomarkers.
Citation Format: Sylvie Sauvaigo, Giovanna Muggiolu, Sarah Libert, Elisabeth Daguenet, Claire Rodriguez-Lafrasse, Thierry Maillet, Nicolas Magné. Prospective study for the identification of DNA repair radiotoxicity biomarkers in breast and prostate cancer patients: Cohort description and descriptive statistics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 681.
Collapse
Affiliation(s)
| | | | | | - Elisabeth Daguenet
- 2Institut de cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | | | | | - Nicolas Magné
- 2Institut de cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| |
Collapse
|
15
|
Muggiolu G, Libert L, Daguenet E, Maillet T, Rodriguez-Lafrasse C, Sauvaigo S, Magné N. Abstract 680: A DNA repair biomarker signature to predict radiotherapy side-effects in breast and prostate cancers. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: About 50% of patients with solid tumors receive radiotherapy (RT) which induces cancer cells death through radiation-induced DNA damage. Five to 10% of these patients experience severe toxicity that can heavily impact their quality of life. The identification of predictive biomarkers to discriminate patients at high risk of developing radiotoxicity is needed to move towards a personalized treatment and to improve the management of these patients.
Purpose: The aim of this clinical proof-of-concept was to identify blood radiotoxicity biomarkers based on a comprehensive analysis of several DNA repair activities. We relied on the hypothesis that DNA damage, DNA repair and inflammation are functionally associated and mutually supportive, and related to the appearance of side effects.
Methods: 200 patients with either prostate or breast cancer who underwent RT were enrolled at the Lucien Neuwirth Cancer institute. Late radio-induced adverse events were recorded 6 months after the beginning of the treatment. Three blood samples per patient were collected before and early during the treatment course to monitor the ability of enzymes contained in lymphocytes to repair series of DNA lesions immobilized on biochip (Glyco-SPOT assay). We analyzed the association between the Base Excision Repair (BER), the primary pathway responsible for DNA repair during inflammation, and the appearance of severe late radiation-induced effects (3 in the female and 4 in the male cohort).
Results: Late severe (Grade ≥3) and late moderate (Grade ≥2) radiation-induced events were recorded. Cutaneous, and gastro-intestinal and genitourinary adverse events, were considered respectively in breast cancer and prostate cancer patients. We observed some significantly lower BER activities in breast cancer patients who developed severe late events compared to those who did not. By contrast, it was the opposite in prostate cancer patients. In both cohort we defined a combination of biomarkers that predicted the appearance of severe late adverse events with 100% sensitivity and 100% negative predictive value using the blood sample taken after the first dose of RT.
Conclusion: The risk of late radiotoxicity could be accurately predicted on the basis of combination of BER-related biomarkers. Interestingly, the biomarkers differed in breast and prostate cancer patients suggesting that beyond inflammation, hormone pathway regulation impacted the BER response to ionizing radiation, and the relationship with long-term severe side effects. These results require confirmation on a larger cohort.
Citation Format: Giovanna Muggiolu, Libert Libert, Elisabeth Daguenet, Thierry Maillet, Claire Rodriguez-Lafrasse, Sylvie Sauvaigo, Nicolas Magné. A DNA repair biomarker signature to predict radiotherapy side-effects in breast and prostate cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 680.
Collapse
Affiliation(s)
| | | | - Elisabeth Daguenet
- 2Institut de cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | | | | | | | - Nicolas Magné
- 2Institut de cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| |
Collapse
|
16
|
Courtois E, Bouleftour W, Guy JB, Louati S, Bensadoun RJ, Rodriguez-Lafrasse C, Magné N. Mechanisms of PhotoBioModulation (PBM) focused on oral mucositis prevention and treatment: a scoping review. BMC Oral Health 2021; 21:220. [PMID: 33926421 PMCID: PMC8086292 DOI: 10.1186/s12903-021-01574-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 04/19/2021] [Indexed: 01/10/2023] Open
Abstract
Background Oral mucositis (OM) is a severe complication cancer patients undergo when treated with chemoradiotherapy. Photobiomodulation (PBM) therapy also known as low-level laser therapy has been increasingly used for the treatment of such oral toxicity. The aim of this review is to discuss the mechanisms of photobiomodulation (PBM) regarding OM prevention and treatment, and more precisely to focus on the effect of PBM on tumor and healthy cells. Methods MEDLINE/PubMed, and google scholar were searched electronically. Selected studies were focusing on PBM effects on tumor and healthy cells. Results PBM interactions with the tissue and additional mechanism in OM therapy were detailed in this review. Moreover, this review highlighted a controversy about the carcinogenic effect of PBM. Indeed, Many studies reported that PBM could enhance malignant cell proliferation; suggesting that PBM would have no protective effect. In addition to acting on cancer cells, PBM may damage healthy cells. Conclusion More prospective studies are needed to assess the effect of PBM on cancer cells in order to improve its use for OM prevention and treatment.
Collapse
Affiliation(s)
| | - Wafa Bouleftour
- Département de Radiothérapie, Institut de Cancérologie de La Loire - Lucien Neuwirth, 42270, St Priest en Jarez, France.
| | - Jean-Baptiste Guy
- Département de Radiothérapie, Institut de Cancérologie de La Loire - Lucien Neuwirth, 42270, St Priest en Jarez, France
| | - Safa Louati
- Département de Radiothérapie, Institut de Cancérologie de La Loire - Lucien Neuwirth, 42270, St Priest en Jarez, France
| | | | - Claire Rodriguez-Lafrasse
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire Et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, 69921, Oullins Cedex, France
| | - Nicolas Magné
- Département de Radiothérapie, Institut de Cancérologie de La Loire - Lucien Neuwirth, 42270, St Priest en Jarez, France.,UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire Et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, 69921, Oullins Cedex, France
| |
Collapse
|
17
|
Guy JB, Espenel S, Louati S, Gauthier A, Garcia MA, Vial N, Malésys C, Ardail D, Alphonse G, Wozny AS, Rodriguez-Lafrasse C, Magné N. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2021; 147:1905-1916. [PMID: 33791846 DOI: 10.1007/s00432-021-03593-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 03/09/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE The clinical outcome of head and neck squamous cell carcinoma (HNSCC) remains poor, partly due to the presence of resistant cancer stem cells (CSCs) which are responsible of recurrences. CSCs have low EGFR expression and, conversely, overexpress the anti-apoptotic Bcl-2 protein, which is involved in resistance to apoptosis and the invasion/migration capacities of tumour cells. METHODS The combination therapy of ABT-199, a Bcl-2 inhibitor, cetuximab an EGFR inhibitor, and radiation using an HNSCC model (SQ20B cell line) and its corresponding CSC subpopulation were evaluated in vitro (2D/3D cell proliferation; invasion/migration and apoptosis using videomicroscopy) and in vivo. RESULTS Cetuximab strongly inhibited 2D and 3D cell proliferation, as well as invasion/migration, only in non-CSC-SQ20B cells, whereas ABT-199 selectively inhibited these mechanisms in SQ20B/CSCs. The combination of irradiation + cetuximab + ABT-199 increased the inhibition of the 2D and 3D cell proliferation, invasion/migration, and resistance to apoptosis in both cell sub-populations. In addition, in a nude mouse model with heterotopic tumour xenograft, a treatment combining cetuximab + ABT-199 with fractional irradiation strongly delayed the tumour growth and increased in vivo lifespan without side effects. CONCLUSION Based on the present results, this triple combination therapy may represent a new opportunity for testing in clinical trials, particularly in locally advanced HNSCC.
Collapse
Affiliation(s)
- Jean-Baptiste Guy
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France.
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France.
- Département de Radiothérapie, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France.
| | - Sophie Espenel
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Département de Radiothérapie, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France
| | - Safa Louati
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Département de Radiothérapie, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France
| | - Arnaud Gauthier
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Hospices Civils de Lyon, 69229, Lyon, France
| | - Max-Adrien Garcia
- Département de Santé Publique, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France
| | - Nicolas Vial
- Département de Radiothérapie, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France
| | - Céline Malésys
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
| | - Dominique Ardail
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Hospices Civils de Lyon, 69229, Lyon, France
| | - Gersende Alphonse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Hospices Civils de Lyon, 69229, Lyon, France
| | - Anne-Sophie Wozny
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Hospices Civils de Lyon, 69229, Lyon, France
| | - Claire Rodriguez-Lafrasse
- Faculté de Médecine-Lyon-Sud, Université Lyon 1, 69921, Oullins, France
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Hospices Civils de Lyon, 69229, Lyon, France
| | - Nicolas Magné
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud, CNRS UMR 5822 IP2I, 165 Chemin du Grand Revoyet, BP 12, 69921, Oullins Cedex, France
- Département de Radiothérapie, Institut de Cancérologie de La Loire, Lucien Neuwirth, 42270, St Priest en Jarez, France
| |
Collapse
|
18
|
Garcia J, Gauthier A, Lescuyer G, Barthelemy D, Geiguer F, Balandier J, Edelstein DL, Jones FS, Holtrup F, Duruisseau M, Grolleau E, Rodriguez-Lafrasse C, Merle P, Couraud S, Payen L. Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM TM EGFR V2 and NGS Technologies. Mol Diagn Ther 2021; 25:239-250. [PMID: 33660188 PMCID: PMC7956937 DOI: 10.1007/s40291-021-00515-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/03/2021] [Indexed: 12/30/2022]
Abstract
Background and Objectives The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding the epidermal growth factor receptor (EGFR) within circulating cell-free DNA is an important first step in determining the eligibility of patients with non-small cell lung cancer to receive tyrosine kinase inhibitors. Methods We present the clinical validation (accuracy, sensitivity, and specificity) of a highly sensitive OncoBEAMTMEGFR V2 test, which we compare to a custom next-generation sequencing assay, for the treatment of patients with non-small cell lung cancer with EGFR tyrosine kinase inhibitor therapies. The OncoBEAMTM digital-polymerase chain reaction method detects 36 different EGFR alterations in circulating cell-free DNA, whereas the next-generation sequencing assay covers major solid tumor oncodrivers. Of the 540 samples analyzed with the OncoBEAMTMEGFR V2 test, 42.4% of patients had undergone molecular testing at diagnosis (N = 229/540) and 57.7% of patients during disease progression (N = 311/540). Results The sensitivity and specificity were measured for this BEAMing assay. The number of mutant beads and mutant allelic fraction were measured for each EGFR alteration and the level of detection was established at 0.1% for a median of 2861 genome equivalent (GE) in each reaction using HD780 horizon control DNA, as well as by an internal quality reference standard. Approximately 10%, 27%, and 63% of the 540 samples contained < 1500 GE, a range of 1500–3000 GE, and > 3000 GE, which corresponded to a maximal assay sensitivity of 2.0%, 0.5–0.1%, and 0.1–0.05% mutant allelic fraction, respectively. In a routine hospital setting, 11.4% of non-small cell lung cancer tumors were positive at diagnosis for EGFR alterations, while 43.7% samples harbored EGFR mutations at progression, among which 40.3% expressed EGFR resistance mutations after first-line tyrosine kinase inhibitor treatment with first- and second-generation drugs. Conclusions The OncoBEAMTMEGFR V2 is a sensitive, robust, and accurate assay that delivers reproducible results. Next-generation sequencing and BEAMing technologies act complementarily in the routine molecular screening. We show that using a next-generation sequencing assay, despite its lower sensitivity, enables the identification of rare EGFR alterations or resistance mechanisms (mutation, deletion, insertion, and copy number variation) to orient first- and second-line treatments. Supplementary Information The online version contains supplementary material available at 10.1007/s40291-021-00515-9.
Collapse
Affiliation(s)
- Jessica Garcia
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France
| | - Arnaud Gauthier
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Gaëlle Lescuyer
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France
| | - David Barthelemy
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France
| | - Florence Geiguer
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France
| | - Julie Balandier
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France
| | - Daniel L Edelstein
- Life Sciences Medical Affairs and Research and Development Sysmex Inostics, GmBH, Hamburg, Germany
| | - Frederick S Jones
- Life Sciences Medical Affairs and Research and Development Sysmex Inostics, GmBH, Hamburg, Germany
| | - Frank Holtrup
- Life Sciences Medical Affairs and Research and Development Sysmex Inostics, GmBH, Hamburg, Germany
| | - Mickael Duruisseau
- Service de Pneumologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Emmanuel Grolleau
- Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique, Groupement Hospitalier Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite, France
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Patrick Merle
- Service de Pneumologie, Centre Hospitalier Gabriel Montpied, Clermont-Ferrand, France
| | - Sébastien Couraud
- Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France.,Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique, Groupement Hospitalier Sud, Institut de Cancérologie des Hospices Civils de Lyon, Pierre-Bénite, France.,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, Université de Lyon, Oullins, France
| | - Léa Payen
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France. .,Hospices Civils de Lyon Cancer Institute, CIRculating CANcer (CIRCAN) Program, Pierre-Bénite, France. .,Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 165, Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
| |
Collapse
|
19
|
Courtois E, Guy JB, Axisa F, Saint-Girons P, Alston L, Houmera N, Bensadoun RJ, Visbecq A, Rodriguez-Lafrasse C, Magné N. Photobiomodulation by a new optical fiber device: analysis of the in vitro impact on proliferation/migration of keratinocytes and squamous cell carcinomas cells stressed by X-rays. Lasers Med Sci 2020; 36:1445-1454. [PMID: 33169275 DOI: 10.1007/s10103-020-03185-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 11/03/2020] [Indexed: 01/15/2023]
Abstract
Photobiomodulation-based (PBM-based) therapies show promising results in mucositis and dermatitis treatment by stimulating wound healing mechanisms such as cell proliferation and migration. The aim of the present study is to investigate the in vitro effects of CareMin650 on the proliferation and migration of two different types of cells, namely cancer and non-cancer cells, with or without X-ray radiation. Study design used PBM through a combination of 0-3-6 J/cm2 doses-with or without X-ray radiation-on the proliferation and migration capabilities of a keratinocyte cell line (HaCaT) and a squamous cell carcinoma line (SCC61). PBM is delivered by a new woven optical fiber device, namely CareMin650 prototype (light emission by LEDs (light-emitting diodes), peak at 660 nm, irradiance of 21.6 mW/cm2). The effectiveness of PBM to increase HaCaT proliferation and migration (with or without X-ray radiation) supports the capability of PBM to favor wound healing. It also highlights that PBM does not provide any anti-radiation effect to previously X-rays radiated SCC (p < 0.001). Such data supports the beneficial effect of PBM delivered by an optical fiber device to heal wounds, without promoting cancer development.
Collapse
Affiliation(s)
| | - Jean-Baptiste Guy
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France.,Département de Radiothérapie, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42270, Saint-Priest en Jarez cedex, France
| | | | | | | | - Narimène Houmera
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France.,Département de Radiothérapie, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42270, Saint-Priest en Jarez cedex, France
| | | | | | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France
| | - Nicolas Magné
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France. .,Département de Radiothérapie, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42270, Saint-Priest en Jarez cedex, France.
| |
Collapse
|
20
|
Daguenet E, Khalifa J, Tolédano A, Borchiellini D, Pointreau Y, Rodriguez-Lafrasse C, Chargari C, Magné N. To exploit the 5 'R' of radiobiology and unleash the 3 'E' of immunoediting: 'RE'-inventing the radiotherapy-immunotherapy combination. Ther Adv Med Oncol 2020; 12:1758835920913445. [PMID: 32426043 PMCID: PMC7222228 DOI: 10.1177/1758835920913445] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Affiliation(s)
- Elisabeth Daguenet
- Department of Radiotherapy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
- University Department of Research and Teaching, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Jonathan Khalifa
- Department of Radiotherapy, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse, Oncopôle, Toulouse, France
| | - Alain Tolédano
- Department of Radiotherapy, Hartmann Radiotherapy Center, American Hospital of Paris, Neuilly, France
| | - Delphine Borchiellini
- Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d’Azur, Nice, France
| | - Yoann Pointreau
- Department of Radiotherapy, Institut Inter-régional de Cancérologie, Centre Jean Bernard-Clinique Victor Hugo, Le Mans, France
| | - Claire Rodriguez-Lafrasse
- Laboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IN2P3, IPNL, PRISME, Villeurbanne, France
- Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France
| | - Cyrus Chargari
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
- Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
- French Military Health Services Academy, Ecole du Val-de-Grâce, Paris, France
| | | |
Collapse
|
21
|
Simonet S, Rodriguez-Lafrasse C, Beal D, Gerbaud S, Malesys C, Tillement O, Lux F, Fayyad-Kazan H, Rachidi W, Ardail D. Gadolinium-Based Nanoparticles Can Overcome the Radioresistance of Head and Neck Squamous Cell Carcinoma Through the Induction of Autophagy. J Biomed Nanotechnol 2020; 16:111-124. [PMID: 31996290 DOI: 10.1166/jbn.2020.2871] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Radiation therapy is a mainstay in the therapeutic management of Head and Neck Squamous Cell Carcinoma (HNSCC). Despite significant progress in this field, radioresistance still accounts for most treatment failures. Gadolinium-based nanoparticles (GBNs) have shown great promises as radiosensitizers but the underlying sensitizing mechanism is still largely unknown with regards to the disparities obtained in in vitro studies. In this study, we show that a new formulation of GBNs, AGuIX®, can radiosensitize HNSCC after cell uptake and further accumulation in lysosomes. Although radiation alone triggered late apoptosis and mitochondrial impairment, the pre-treatment with GBNs led to complex DNA damage and a specific increase of autophagic cell death. In addition, a significant radio-enhancement effect was obtained after the pre-conditioning of cells with a glutathione inhibitor before GBNs treatment and radiation exposure. Overall, our results provide additional information on the radio-enhancing properties of GBNs in the management of radioresistant HNSCC.
Collapse
|
22
|
Soumboundou M, Nkengurutse I, Dossou J, Colicchio B, Djebou C, Gadji M, Houenon G, Dem A, Dedjan A, Diarra M, Adjibade R, Finot F, Hempel W, Dieterlen A, Jeandidier E, Rodriguez-Lafrasse C, M'kacher R. Biological Dosimetry Network in Africa: Establishment of a Dose-Response Curve Using Telomere and Centromere Staining. Health Phys 2019; 117:618-624. [PMID: 31211757 DOI: 10.1097/hp.0000000000001102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
PURPOSE Biological dosimetry, based on the relationship between the absorbed dose after exposure to ionizing radiation and the frequency of scored aberrations, has been and continues to be an important tool for estimating the dose after exposure. Dicentric chromosomes are considered to be the most specific and sensitive aberration related to radiation exposure. Here, we established the dose-response curve following in vitro irradiation of circulating lymphocytes from healthy donors from three African countries after scoring unstable chromosomal aberrations. MATERIALS AND METHODS Blood samples from 16 African donors were exposed to various doses (0 to 4 Gy) using an X-RAD320 x-ray system with a maximum photon energy of 250 kV at a dose rate of 0.1 Gy min. Blood lymphocytes were cultured for 48 h, and chromosomal aberrations were scored during the first mitosis by telomere and centromere staining. The distribution of dicentric chromosomes was determined. RESULTS No dicentric chromosomes were found after the analysis of 2,669 first-division metaphases before in vitro exposure. We established a linear-quadratic dose-response curve based on the frequency of dicentric and ring chromosomes and calculated double-strand breaks, taking into account all scored aberrations. CONCLUSION The generation of a specific dose-response curve for African donors will allow the practice of precise biological dosimetry in these countries. This work is the first step towards realizing an African biodosimetry network and the establishment of a biological dosimetry laboratory, which could play a major role in the application of radioprotection norms.
Collapse
Affiliation(s)
- Mamadou Soumboundou
- Laboratoire de Biophysique, UFR-Santé Thiès, Hôpital pour Enfants de Diamniadio, Sénégal
| | | | - Julien Dossou
- Laboratoire de Biologie Appliquée (LARBA)/Unité de Recherche en Carcinogénèse et Morphologie Humaines (URCMH) de l'Ecole Polytechnique de l'Université d'Abomey-Calavi, Bénin
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Catherine Djebou
- Laboratoire de Biologie Appliquée (LARBA)/Unité de Recherche en Carcinogénèse et Morphologie Humaines (URCMH) de l'Ecole Polytechnique de l'Université d'Abomey-Calavi, Bénin
| | - Macoura Gadji
- Laboratoire Hématologie, Université Cheikh Anta DIOP-Dakar, Sénégal
| | - Germain Houenon
- Laboratoire de Biologie Appliquée (LARBA)/Unité de Recherche en Carcinogénèse et Morphologie Humaines (URCMH) de l'Ecole Polytechnique de l'Université d'Abomey-Calavi, Bénin
| | - Ahmadou Dem
- Institut de Cancérologie Marie-Curie, Département Oncologie, Université Cheikh Anta DIOP-Dakar, Sénégal
| | - Alexandre Dedjan
- Laboratoire de Biologie Appliquée (LARBA)/Unité de Recherche en Carcinogénèse et Morphologie Humaines (URCMH) de l'Ecole Polytechnique de l'Université d'Abomey-Calavi, Bénin
| | - Mounibé Diarra
- Laboratoire de Physique-Pharmaceutique, Université Cheikh Anta DIOP-Dakar-Sénégal
| | - Rachad Adjibade
- Laboratoire de Biologie Appliquée (LARBA)/Unité de Recherche en Carcinogénèse et Morphologie Humaines (URCMH) de l'Ecole Polytechnique de l'Université d'Abomey-Calavi, Bénin
| | | | | | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Eric Jeandidier
- Service de Génétique Médicale, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire IPNL, Université de Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | | |
Collapse
|
23
|
Verry C, Porcel E, Chargari C, Rodriguez-Lafrasse C, Balosso J. Utilisation de nanoparticules comme agent radiosensibilisant en radiothérapie : où en est-on ? Cancer Radiother 2019; 23:917-921. [DOI: 10.1016/j.canrad.2019.07.134] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 07/30/2019] [Indexed: 01/18/2023]
|
24
|
Monini C, Alphonse G, Rodriguez-Lafrasse C, Testa É, Beuve M. Comparison of biophysical models with experimental data for three cell lines in response to irradiation with monoenergetic ions. Phys Imaging Radiat Oncol 2019; 12:17-21. [PMID: 33458290 PMCID: PMC7807531 DOI: 10.1016/j.phro.2019.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 10/31/2019] [Accepted: 10/31/2019] [Indexed: 10/29/2022]
Abstract
The relative biological effectiveness (RBE) in particle therapy is currently estimated using biophysical models. We compared experimental measurements to the α curves as function of linear energy transfer computed by the Local Effect Model (LEM I-IV), the Microdosimetric Kinetic Model (MKM) and the NanOx model for HSG, V79 and CHO-K1 cells in response to monoenergetic irradiations. Although the LEM IV and the MKM predictions accurately reproduced the trend observed in the data, NanOx yielded a better agreement than the other models for more irradiation configurations. Its χ 2 estimator was indeed the lowest for three over seven considered cases.
Collapse
Affiliation(s)
- Caterina Monini
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622 Villeurbanne, France
| | - Gersende Alphonse
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622 Villeurbanne, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, 69921 Oullins Cedex, France.,Hospices Civils de Lyon, Service de Biochimie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite, France
| | - Claire Rodriguez-Lafrasse
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622 Villeurbanne, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, 69921 Oullins Cedex, France.,Hospices Civils de Lyon, Service de Biochimie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite, France
| | - Étienne Testa
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622 Villeurbanne, France
| | - Michaël Beuve
- Univ. Lyon, Univ. Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, F-69622 Villeurbanne, France
| |
Collapse
|
25
|
Garcia J, Barthelemy D, Geiguer F, Ballandier J, Li KW, Aurel JP, Le Breton F, Rodriguez-Lafrasse C, Manship B, Couraud S, Payen L. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence. J Vis Exp 2019. [PMID: 31475991 DOI: 10.3791/59873] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Circulating tumor cells (CTCs) derived from the primary tumor are shed into the bloodstream or lymphatic system. These rare cells (1-10 cells per mL of blood) warrant a poor prognosis and are correlated with shorter overall survival in several cancers (e.g., breast, prostate and colorectal). Currently, the anti-EpCAM-coated magnetic bead-based CTC capturing system is the gold standard test approved by the U.S. Food and Drug Administration (FDA) for enumerating CTCs in the bloodstream. This test is based on the use of magnetic beads coated with anti-EpCAM markers, which specifically target epithelial cancer cells. Many studies have illustrated that EpCAM is not the optimal marker for CTC detection. Indeed, CTCs are a heterogeneous subpopulation of cancer cells and are able to undergo an epithelial-to-mesenchymal transition (EMT) associated with metastatic proliferation and invasion. These CTCs are able to reduce the expression of cell surface epithelial marker EpCAM, while increasing mesenchymal markers such as vimentin. To address this technical hurdle, other isolation methods based on physical properties of CTCs have been developed. Microfluidic technologies enable a label-free approach to CTC enrichment from whole blood samples. The spiral microfluidic technology uses the inertial and Dean drag forces with continuous flow in curved channels generated within a spiral microfluidic chip. The cells are separated based on the differences in size and plasticity between normal blood cells and tumoral cells. This protocol details the different steps to characterize the programmed death-ligand 1 (PD-L1) expression of CTCs, combining a spiral microfluidic device with customizable immunofluorescence (IF) marker set.
Collapse
Affiliation(s)
- Jessica Garcia
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon; Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute; University of Lyon, Claude Bernard University, Cancer Research Center of Lyon
| | - David Barthelemy
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon; Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute; University of Lyon, Claude Bernard University, Cancer Research Center of Lyon
| | - Florence Geiguer
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon; Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute
| | - Julie Ballandier
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon; Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute; University of Lyon, Claude Bernard University, Cancer Research Center of Lyon
| | | | | | | | | | - Brigitte Manship
- University of Lyon, Claude Bernard University, Cancer Research Center of Lyon
| | - Sébastien Couraud
- Acute Respiratory Disease and Thoracic Oncology Department, Lyon Sud Hospital, Hospices Civils de Lyon Cancer Institute; EMR-3738 Therapeutic Targeting in Oncology, Lyon Sud Medical Faculty, Lyon 1 University
| | - Léa Payen
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon; Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon Cancer Institute; University of Lyon, Claude Bernard University, Cancer Research Center of Lyon;
| |
Collapse
|
26
|
Garcia J, Wozny AS, Geiguer F, Delherme A, Barthelemy D, Merle P, Tissot C, Jones FS, Johnson C, Xing X, Xu Z, Edelstein DL, Brevet M, Souquet PJ, Rodriguez-Lafrasse C, Payen L, Couraud S. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells. Cancer Med 2019; 8:3685-3697. [PMID: 31112372 PMCID: PMC6866744 DOI: 10.1002/cam4.2244] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 04/12/2019] [Accepted: 04/26/2019] [Indexed: 12/12/2022] Open
Abstract
Cell-free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) have demonstrated tremendous potential for molecular diagnosis of cancer and have been rapidly implemented in specific settings. However, widespread clinical adoption still faces some obstacles. The purpose was to compare the performance of a BEAMing (beads, emulsion, amplification, and magnetics) assay (OncoBEAM™-epidermal growth factor receptor [EGFR] [Sysmex Inostics]) and a next-generation sequencing assay (NGS; 56G Oncology panel kit, Swift Bioscience) to detect the p.T790M EGFR mutation in cfDNA of non-small cell lung cancer (NSCLC) patients. CfDNA samples (n = 183) were collected within our hospital from patients having a known EGFR sensitizing mutation, and presenting disease progression while under first-line therapy. EGFR mutations were detected using NGS in 42.1% of samples during progression in cfDNA. Testing using the OncoBEAM™-EGFR assay enabled detection of the p.T790M EGFR mutation in 40/183 NSCLC patients (21.8%) versus 20/183 (10.9%), using the NGS assay. Samples that were only positive with the OncoBEAM™-EGFR assay had lower mutant allelic fractions (Mean = 0.1304%; SD ± 0.1463%). In addition, we investigated the detection of p.T790M in mCTCs using H1975 cells. These cells spiked into whole blood were enriched using the ClearCellFX1 microfluidic device. Using the OncoBEAM™-EGFR assay, p.T790M was detected in as few as 1.33 tumoral cells/mL. Overall, these findings highlight the value of using the OncoBEAM™-EGFR to optimize detection of the p.T790M mutation, as well as the complementary clinical value that each of the mutation detection assay offers: NGS enabled the detection of mutations in other oncogenes that may be relevant to secondary resistance mechanisms, whereas the OncoBEAM™-EGFR assay achieved higher sensitivity for detection of clinically actionable mutations.
Collapse
Affiliation(s)
- Jessica Garcia
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, University of Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Anne-Sophie Wozny
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France
| | - Florence Geiguer
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Aurélia Delherme
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - David Barthelemy
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, University of Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Patrick Merle
- Service de Pneumologie et oncologie thoracique, CHU G Montpied, Clermont-Ferrand, France
| | - Claire Tissot
- Service de Pneumologie et Cancérologie Thoracique, CHU Saint Etienne, Saint-Priest-en-Jarez, France
| | | | | | - Xiaobin Xing
- SOPHiA GENETICS SA, Headquarters, Saint Sulpice, Switzerland
| | - Zhenyu Xu
- SOPHiA GENETICS SA, Headquarters, Saint Sulpice, Switzerland
| | | | - Marie Brevet
- Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, University of Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Institut de pathologie multisites des HCL-Site Est, Hospices Civils de Lyon, Lyon, France
| | - Pierre-Jean Souquet
- Service de Pneumologie aigue spécialisée et cancérologie thoracique, Groupement hospitalier sud, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,UMR CNRS 5822/IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1, Lyon, France
| | - Léa Payen
- Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.,Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, University of Lyon, Lyon, France.,CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Sébastien Couraud
- CIRculating CANcer (CIRCAN) program, Hospices Civils de Lyon Cancer institute, Lyon, France.,Service de Pneumologie aigue spécialisée et cancérologie thoracique, Groupement hospitalier sud, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France.,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de médecine Lyon Sud, Université Lyon 1, Université de Lyon, Lyon, France
| |
Collapse
|
27
|
Wozny AS, Vares G, Alphonse G, Lauret A, Monini C, Magné N, Cuerq C, Fujimori A, Monboisse JC, Beuve M, Nakajima T, Rodriguez-Lafrasse C. ROS Production and Distribution: A New Paradigm to Explain the Differential Effects of X-ray and Carbon Ion Irradiation on Cancer Stem Cell Migration and Invasion. Cancers (Basel) 2019; 11:cancers11040468. [PMID: 30987217 PMCID: PMC6521340 DOI: 10.3390/cancers11040468] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 03/26/2019] [Accepted: 04/01/2019] [Indexed: 02/06/2023] Open
Abstract
Although conventional radiotherapy promotes the migration/invasion of cancer stem cells (CSCs) under normoxia, carbon ion (C-ion) irradiation actually decreases these processes. Unraveling the mechanisms of this discrepancy, particularly under the hypoxic conditions that pertain in niches where CSCs are preferentially localized, would provide a better understanding of the origins of metastases. Invasion/migration, proteins involved in epithelial-to-mesenchymal transition (EMT), and expression of MMP-2 and HIF-1α were quantified in the CSC subpopulations of two head-and-neck squamous cell carcinoma (HNSCC) cell lines irradiated with X-rays or C-ions. X-rays triggered HNSCC-CSC migration/invasion under normoxia, however this effect was significantly attenuated under hypoxia. C-ions induced fewer of these processes in both oxygenation conditions. The differential response to C-ions was associated with a lack of HIF-1α stabilization, MMP-2 expression, or activation of kinases of the main EMT signaling pathways. Furthermore, we demonstrated a major role of reactive oxygen species (ROS) in the triggering of invasion/migration in response to X-rays. Monte-Carlo simulations demonstrated that HO● radicals are quantitatively higher after C-ions than after X-rays, however they are very differently distributed within cells. We postulate that the uniform distribution of ROS after X-rays induces the mechanisms leading to invasion/migration, which ROS concentrated in C-ion tracks are unable to trigger.
Collapse
Affiliation(s)
- Anne-Sophie Wozny
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins Cedex, France.
- Centre Hospitalier Lyon-Sud, Service de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
| | - Guillaume Vares
- Advanced Medical Instrumentation Unit, Okinawa Institute of Science and Technology Graduate University, Okinawa 904-0495, Japan.
- Department of Radiation Effects Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Inage-ku, Chiba 263-8555, Japan.
| | - Gersende Alphonse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins Cedex, France.
- Centre Hospitalier Lyon-Sud, Service de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
| | - Alexandra Lauret
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins Cedex, France.
| | - Caterina Monini
- Univ Lyon, Université Lyon 1, UMR CNRS5822 /IN2P3, IPNL, PRISME, PHABIO, 69322 Villeurbanne, France.
| | - Nicolas Magné
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins Cedex, France.
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, 42270 St Priest en Jarez, France.
| | - Charlotte Cuerq
- Centre Hospitalier Lyon-Sud, Service de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
| | - Akira Fujimori
- Department of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Inage-ku, 263-8555 Chiba, Japan.
| | - Jean-Claude Monboisse
- Université de Reims Champagne-Ardenne, CNRS UMR 7369, CHU de Reims, 51100 Reims, France.
| | - Michael Beuve
- Univ Lyon, Université Lyon 1, UMR CNRS5822 /IN2P3, IPNL, PRISME, PHABIO, 69322 Villeurbanne, France.
| | - Tetsuo Nakajima
- Department of Radiation Effects Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Inage-ku, Chiba 263-8555, Japan.
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins Cedex, France.
- Centre Hospitalier Lyon-Sud, Service de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
| |
Collapse
|
28
|
Garcia J, Delherme A, Geigeur F, Merle P, Tissot C, Jones F, Edelstein D, Souquet PJ, Rodriguez-Lafrasse C, Couraud S, Payen L, Xu Z. Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. AGuIX ® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol 2018; 92:20180365. [PMID: 30226413 PMCID: PMC6435081 DOI: 10.1259/bjr.20180365] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.
Collapse
Affiliation(s)
- François Lux
- NH TherAguix SAS, Villeurbanne, France.,Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| | - Vu Long Tran
- Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France.,Nano-H SAS, Saint-Quentin-Fallavier, France
| | - Eloïse Thomas
- Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| | | | - Fabien Rossetti
- Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| | - Matteo Martini
- Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| | - Charles Truillet
- Imagerie Moléculaire In Vivo, Inserm, CEA, CNRS, Univ Paris Sud, Université Paris Saclay - Service Hospitalier Frédéric Joliot, Orsay, France
| | | | - Guillaume Bort
- Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| | - Franck Denat
- Institut de Chimie Moléculaire, Université de Bourgogne, Dijon, France
| | | | - Goran Angelovski
- MR Neuroimaging Agents, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
| | - Alexandre Detappe
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA, USA
| | - Yannick Crémillieux
- Centre de Résonance Magnétique des Systèmes Biologiques, CNRS UMR, Université Bordeaux, Bordeaux, France
| | - Nathalie Mignet
- Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.,CNRS, UTCBS UMR , Paris, France.,Université Paris Descartes Sorbonne-Paris-Cité, Paris, France.,INSERM, UTCBS U 1022, Paris, France
| | - Bich-Thuy Doan
- Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.,CNRS, UTCBS UMR , Paris, France.,Université Paris Descartes Sorbonne-Paris-Cité, Paris, France.,INSERM, UTCBS U 1022, Paris, France
| | - Benoit Larrat
- NeuroSpin, CEA Saclay, Gif-sur-Yvette, France.,Université Paris-Saclay, Orsay, France
| | - Sébastien Meriaux
- NeuroSpin, CEA Saclay, Gif-sur-Yvette, France.,Université Paris-Saclay, Orsay, France
| | - Emmanuel Barbier
- INSERM, Univ. Grenoble Alpes, Grenoble Institut des Neurosciences , Grenoble, France
| | - Stéphane Roux
- Institut UTINAM, UMR CNRS 6213-Université de Bourgogne Franche-Comté, Besançon, France
| | - Peter Fries
- Clinic of Diagnostic and Interventional Radiology, Saarland University Medical Center, Homburg/Saar, Germany
| | - Andreas Müller
- Clinic of Diagnostic and Interventional Radiology, Saarland University Medical Center, Homburg/Saar, Germany
| | - Marie-Caline Abadjian
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.,Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Carolyn Anderson
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.,Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Emmanuelle Canet-Soulas
- Univ Lyon, CarMeN Laboratory Institut National de la Santé et de la Recherche Médicale U1060,INRA U1397, Université Lyon 1, INSA Lyon, Oullins, France
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center forScientific Research "Demokritos", Aghia Paraskevi, Athens, Greece
| | | | - Céline Frochot
- Laboratoire Réactions et Génie des Procédés, UMR, Université de Lorraine-CNRS, Nancy, France
| | - Camille Verry
- Radiotherapy department, CHU de Grenoble, Grenoble cedex 9, France
| | - Jacques Balosso
- Radiotherapy department, CHU de Grenoble, Grenoble cedex 9, France
| | - Michael Evans
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA
| | | | - Marc Janier
- UNIV Lyon - Université Claude Bernard Lyon 1, Villeurbanne, France.,Hospices Civils de Lyon, plateforme Imthernat, Hôpital Edouard Herriot, Lyon, France
| | - Karl Butterworth
- Centre for Cancer Research and Cell Biology Queen's University Belfast,, Belfast BT9 7AE, UK
| | - Stephen McMahon
- Centre for Cancer Research and Cell Biology Queen's University Belfast,, Belfast BT9 7AE, UK
| | - Kevin Prise
- Centre for Cancer Research and Cell Biology Queen's University Belfast,, Belfast BT9 7AE, UK
| | - Marie-Thérèse Aloy
- IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | - Dominique Ardail
- IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | - Claire Rodriguez-Lafrasse
- IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | - Erika Porcel
- ISMO UMR, Université Paris Saclay, Université Paris Sud, CNRS, Orsay cedex, France
| | - Sandrine Lacombe
- ISMO UMR, Université Paris Saclay, Université Paris Sud, CNRS, Orsay cedex, France
| | - Ross Berbeco
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA, USA
| | - Awatef Allouch
- Cell death and Aging team, Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Laboratory of Molecular Radiotherapy INSERM, Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Université Paris Sud - Paris , rue Edouard Vaillant, Villejuif, France
| | - Jean-Luc Perfettini
- Cell death and Aging team, Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Laboratory of Molecular Radiotherapy INSERM, Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Gustave Roussy, rue Edouard Vaillant, Villejuif, France.,Université Paris Sud - Paris , rue Edouard Vaillant, Villejuif, France
| | - Cyrus Chargari
- French Military Health Academy, Ecole du Val-de-Grâce, Paris, France.,Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France.,Radiotherapy Department, Gustave Roussy, Villejuif, France.,Brachytherapy Unit, Gustave Roussy Cancer Campus, Villejuif, France
| | - Eric Deutsch
- Radiotherapy Department, Gustave Roussy, Villejuif, France.,Brachytherapy Unit, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Olivier Tillement
- NH TherAguix SAS, Villeurbanne, France.,Univ Lyon Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, LYON, France
| |
Collapse
|
30
|
Mery B, Espenel S, Guy JB, Rancoule C, Vallard A, Aloy MT, Rodriguez-Lafrasse C, Magné N. Biological aspects of chondrosarcoma: Leaps and hurdles. Crit Rev Oncol Hematol 2018; 126:32-36. [DOI: 10.1016/j.critrevonc.2018.03.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Revised: 01/31/2018] [Accepted: 03/21/2018] [Indexed: 01/12/2023] Open
|
31
|
Wozny A, Vares G, Nakajima T, Fujimori A, Beuve M, Alphonse G, Rodriguez-Lafrasse C. EP-2281: Role of HIF-1α in the migration/invasion processes in response to photon and C-ion irradiations. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32590-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Moncharmont C, Guy JB, Wozny AS, Gilormini M, Battiston-Montagne P, Ardail D, Beuve M, Alphonse G, Simoëns X, Rancoule C, Rodriguez-Lafrasse C, Magné N. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC). Oncotarget 2018; 7:47738-47749. [PMID: 27374096 PMCID: PMC5216975 DOI: 10.18632/oncotarget.10281] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Accepted: 05/28/2016] [Indexed: 12/12/2022] Open
Abstract
Cancer Stem Cells (CSCs) in Head and Neck Squamous Cell Carcinoma (HNSCC) have extremely aggressive profile (high migratory and invasive potential). These characteristics can explain their resistance to conventional treatment. Efficacy of photon and carbon ion irradiation with addition of cetuximab (5 nM) is studied on clonogenic death, migration and invasion of two HNSCC populations: SQ20B and SQ20B/CSCs. SQ20B express E-cadherin and overexpress EGFR while SQ20B/CSCs express N-cadherin and low EGFR. Cetuximab strongly inhibits SQ20B proliferation but has no effect on SQ20B/CSCs. 2 Gy photon irradiation enhances migration and invasiveness in both populations (p < 0.05), while cetuximab only stops SQ20B migration (p < 0.005). Carbon irradiation significantly inhibits invasion in both populations (p < 0.05), and the association with cetuximab significantly inhibits invasion in both populations (p < 0.005). These results highlight CSCs characteristics: EGFRLow, cetuximab-resistant, and highly migratory. Carbon ion irradiation appears to be a very promising therapeutic modality counteracting migration/invasion process in both parental cells and CSCs in contrast to photon irradiation.
Collapse
Affiliation(s)
- Coralie Moncharmont
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth, St Priest en Jarez, 42270, France
| | - Jean-Baptiste Guy
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth, St Priest en Jarez, 42270, France
| | - Anne-Sophie Wozny
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Hospices Civils de Lyon, Lyon, 69229, France
| | - Marion Gilormini
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France
| | - Priscilla Battiston-Montagne
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France
| | - Dominique Ardail
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Hospices Civils de Lyon, Lyon, 69229, France
| | - Michael Beuve
- Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France
| | - Gersende Alphonse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Hospices Civils de Lyon, Lyon, 69229, France
| | - Xavier Simoëns
- Département de Pharmacologie Clinique et d'Innovation, Institut de Cancérologie de la Loire - Lucien Neuwirth, St Priest en Jarez, 42270, France
| | - Chloé Rancoule
- Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth, St Priest en Jarez, 42270, France
| | - Claire Rodriguez-Lafrasse
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Hospices Civils de Lyon, Lyon, 69229, France
| | - Nicolas Magné
- Université Lyon 1, Faculté de Médecine-Lyon-Sud, Oullins, 69921, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne, 69622, France.,Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth, St Priest en Jarez, 42270, France
| |
Collapse
|
33
|
Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, Guihard S, Meyronet D, Foy JP, Saintigny P, Ledrappier S, Jung A, Rimokh R, Rodriguez-Lafrasse C, Poncet D. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget 2018; 7:44023-44038. [PMID: 27281619 PMCID: PMC5190076 DOI: 10.18632/oncotarget.9829] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 04/10/2016] [Indexed: 12/30/2022] Open
Abstract
At the time of diagnosis, 60% of patients with head and neck squamous cell carcinoma (HNSCC) present tumors in an advanced stage (III-IV) of disease and 80% will relapse within the first two years post-treatment, due to their frequent radio(chemo)resistance. To identify new molecular targets and companion biomarkers, we have investigated the miRNome of 75 stage III-IV oropharynx tumors without relapse (R) or with loco-regional relapse (non-responder, NR) within two years post-treatment. Interestingly, miR-422a was significantly downregulated in NR tumors, in agreement with the increase in cell proliferation and adhesion induced by miR-422a inhibition in vitro. Furthermore, we identified CD73/NT5E oncogene as target of miR-422a. Indeed, modulation of the endogenous level of miR-422a inversely influences the expression and the enzymatic activity of CD73. Moreover, knocking down CD73 mimics the effects of miR-422a upregulation. Importantly, in tumors, miR-422a and CD73 expression levels are inversely correlated, and both are predictive of relapse free survival - especially considering loco(regional) recurrence - in vitro two independent cohorts of advanced oropharynx or HNSCC (N=255) tumors. In all, we reported, for the first time, that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of HNSCC tumors and are new targets for personalized medicine.
Collapse
Affiliation(s)
- Nathalie Bonnin
- Hospices Civils de Lyon, Lyon, France.,EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France
| | - Emma Armandy
- EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France
| | - Julien Carras
- Hospices Civils de Lyon, Lyon, France.,EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France
| | - Sylvain Ferrandon
- EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France
| | - Priscillia Battiston-Montagne
- EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France
| | - Marc Aubry
- Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France.,Plate-forme Génomique Environnementale & Humaine Biogenouest, Biosit/OSUR, Rennes, France.,CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France
| | - Sébastien Guihard
- Laboratory for Tumor Biology and Tumor Bank Paul Strauss Cancer Center, EA3430 of The University of Strasbourg, Strasbourg, France
| | - David Meyronet
- Hospices Civils de Lyon, Lyon, France.,Université de Lyon, Lyon, France.,“Stem Cell Transcriptomic Diversity” Team, Cancer Research Center of Lyon (CRCL), INSERM 1052-CNRS 5286, Lyon, France
| | - Jean-Philippe Foy
- Department of Translational Research and Innovation, CRCL, INSERM 1052-CNRS 5286, Lyon, France
| | - Pierre Saintigny
- Department of Translational Research and Innovation, CRCL, INSERM 1052-CNRS 5286, Lyon, France
| | - Sonia Ledrappier
- Laboratory for Tumor Biology and Tumor Bank Paul Strauss Cancer Center, EA3430 of The University of Strasbourg, Strasbourg, France
| | - Alain Jung
- Laboratory for Tumor Biology and Tumor Bank Paul Strauss Cancer Center, EA3430 of The University of Strasbourg, Strasbourg, France
| | - Ruth Rimokh
- “Signalization Metabolism and Tumor Progression” Team, CRCL, INSERM 1052-CNRS 5286, Lyon, France
| | - Claire Rodriguez-Lafrasse
- EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France.,Biochemistry Department, Transfer and Molecular Oncology Unit, South Lyon Hospital, Hospices Civils de Lyon, Pierre Bénite, Lyon, France
| | - Delphine Poncet
- EMR3738, Equipe de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon Sud - Charles Mérieux, Oullins, France.,Université de Lyon, Lyon, France.,“Signalization Metabolism and Tumor Progression” Team, CRCL, INSERM 1052-CNRS 5286, Lyon, France.,Biochemistry Department, Transfer and Molecular Oncology Unit, South Lyon Hospital, Hospices Civils de Lyon, Pierre Bénite, Lyon, France
| |
Collapse
|
34
|
Gilormini M, Malesys C, Armandy E, Manas P, Guy JB, Magné N, Rodriguez-Lafrasse C, Ardail D. Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC. Oncotarget 2017; 7:16731-44. [PMID: 26934442 PMCID: PMC4941347 DOI: 10.18632/oncotarget.7744] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Accepted: 01/13/2016] [Indexed: 12/26/2022] Open
Abstract
Head and neck squamous cell carcinomas (HNSCC) are common human malignancies with poor clinical outcomes. The 5-year survival rates for patients with advanced stage HNSCC have not changed appreciably in the past few decades, underscoring a dire need for improved therapeutic options. HNSCC is frequently characterized by overexpression of anti-apoptotic Bcl-2 family members. Increased levels of these anti-apoptotic proteins have been associated with radio- and chemoresistance and poor clinical outcome. The aim of this study was to evaluate combined effects of radiation and ABT-737, a BH3-mimetic molecule, in HNSCC. Although ABT-737, as a single agent, was largely ineffective at promoting HNSCC cell death, we found that combining ABT-737 and radiation induced strong synergistic apoptosis in HNSCC cell lines and delayed tumoral growth in vivo. Moreover, we demonstrated for the first time that ABT-737, alone or in combination with radiation, can efficiently eliminate cancer stem cells (CSCs). Altogether, our results indicate that therapy targeting anti-apoptotic Bcl-2 family members could be a highly effective potential adjuvant to radiotherapy capable of targeting CSCs in HNSCC and therefore overcoming cancer recurrence and metastasis.
Collapse
Affiliation(s)
- Marion Gilormini
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France
| | - Céline Malesys
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France
| | - Emma Armandy
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France
| | - Patrick Manas
- UMS3444 BioSciences Gerland-Lyon Sud, PBES, Lyon, France
| | - Jean-Baptiste Guy
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France
| | - Nicolas Magné
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France.,Institut de Cancérologie L. Neuwirth, St Etienne, France
| | - Claire Rodriguez-Lafrasse
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France.,Hospices-Civils-de-Lyon, CHLS, Pierre-Bénite, France
| | - Dominique Ardail
- Université Lyon I, Faculté de Médecine-Lyon-Sud, Oullins, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, EMR3738, Oullins, France.,Hospices-Civils-de-Lyon, CHLS, Pierre-Bénite, France
| |
Collapse
|
35
|
Guy JB, Espenel S, Vallard A, Battiston-Montagne P, Wozny AS, Ardail D, Alphonse G, Rancoule C, Rodriguez-Lafrasse C, Magne N. Evaluation of the Cell Invasion and Migration Process: A Comparison of the Video Microscope-based Scratch Wound Assay and the Boyden Chamber Assay. J Vis Exp 2017. [PMID: 29286429 DOI: 10.3791/56337] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The invasion and migration abilities of tumor cells are main contributors to cancer progression and recurrence. Many studies have explored the migration and invasion abilities to understand how cancer cells disseminate, with the aim of developing new treatment strategies. Analysis of the cellular and molecular basis of these abilities has led to the characterization of cell mobility and the physicochemical properties of the cytoskeleton and cellular microenvironment. For many years, the Boyden chamber assay and the scratch wound assay have been the standard techniques to study cell invasion and migration. However, these two techniques have limitations. The Boyden chamber assay is difficult and time consuming, and the scratch wound assay has low reproducibility. Development of modern technologies, especially in microscopy, has increased the reproducibility of the scratch wound assay. Using powerful analysis systems, an "in-incubator" video microscope can be used to provide automatic and real-time analysis of cell migration and invasion. The aim of this paper is to report and compare the two assays used to study cell invasion and migration: the Boyden chamber assay and an optimized in vitro video microscope-based scratch wound assay.
Collapse
Affiliation(s)
- Jean-Baptiste Guy
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth
| | - Sophie Espenel
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth
| | - Alexis Vallard
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth
| | - Priscillia Battiston-Montagne
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1
| | - Anne-Sophie Wozny
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud
| | - Dominique Ardail
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud
| | - Gersende Alphonse
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud
| | - Chloé Rancoule
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth
| | - Claire Rodriguez-Lafrasse
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud
| | - Nicolas Magne
- UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Université Lyon 1; Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth;
| |
Collapse
|
36
|
Vallard A, Rancoule C, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N. [Biomarkers of radiation-induced DNA repair processes]. Bull Cancer 2017; 104:981-987. [PMID: 29132682 DOI: 10.1016/j.bulcan.2017.09.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Accepted: 09/21/2017] [Indexed: 12/18/2022]
Abstract
The identification of DNA repair biomarkers is of paramount importance. Indeed, it is the first step in the process of modulating radiosensitivity and radioresistance. Unlike tools of detection and measurement of DNA damage, DNA repair biomarkers highlight the variations of DNA damage responses, depending on the dose and the dose rate. The aim of the present review is to describe the main biomarkers of radiation-induced DNA repair. We will focus on double strand breaks (DSB), because of their major role in radiation-induced cell death. The most important DNA repair biomarkers are DNA damage signaling proteins, with ATM, DNA-PKcs, 53BP1 and γ-H2AX. They can be analyzed either using immunostaining, or using lived cell imaging. However, to date, these techniques are still time and money consuming. The development of "omics" technologies should lead the way to new (and usable in daily routine) DNA repair biomarkers.
Collapse
Affiliation(s)
- Alexis Vallard
- Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, , 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France
| | - Chloé Rancoule
- Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, , 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France
| | - Jean-Baptiste Guy
- Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, , 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France
| | - Sophie Espenel
- Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, , 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France
| | | | - Claire Rodriguez-Lafrasse
- Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France
| | - Nicolas Magné
- Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, , 108, bis avenue Albert-Raimond, BP60008, 42271 Saint-Priest-en-Jarez cedex, France; Institut de physique nucléaire de Lyon, IPNL, CNRS-UMR-5822, laboratoire de radiobiologie cellulaire et moléculaire, 69622 Villeurbanne, France.
| |
Collapse
|
37
|
Trone JC, Espenel S, Rehailia-Blanchard A, Guillaume E, Vial N, Rancoule C, Rodriguez-Lafrasse C, Ben Mrad M, El Meddeb Hamrouni A, Ollier E, Chargari C, Deutsch E, Vallard A, Magné N. Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy. Ann Oncol 2017; 28:2691-2697. [PMID: 29045516 DOI: 10.1093/annonc/mdx347] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
BACKGROUND Phase III randomized controlled trials (RCTs) are the cornerstone of evidence-based oncology. However, there is no exhaustive review describing the radiotherapy RTCs characteristics. The objective of the present study was to describe features of all phase III RCTs including at least a radiation therapy. METHODS AND MATERIALS Requests were performed in the Medline database (via PubMed). The latest update was performed in April 2016, using the following MESH terms: 'clinical trials: phase III as topic', 'radiotherapy', 'brachytherapy', as keywords. RESULTS A total of 454 phase III RCTs were identified. Studies were mainly based on open (92.1%) multicenter (77.5%) designs, analyzed in intend to treat (67.6%), aiming at proving superiority (91.6%) through overall survival assessment (46.5%). Most frequently studied malignancies were head and neck (21.8%), lung (14.3%) and prostate cancers (9.9%). Patients were mainly recruited with a locally advanced disease (73.7%). Median age was 59 years old. Out of 977 treatment arms, 889 arms experienced radiotherapy, mainly using 3D-conformal radiotherapy (288 arms, 32.4%). Intensity-modulated techniques were tested in 12 arms (1.3%). The intervention was a non-cytotoxic agent addition in 89 studies (19.6%), a radiation dose/fractionation modification in 74 studies (16.3%), a modification of chemotherapy regimen in 63 studies (13.9%), a chemotherapy addition in 63 studies (13.9%) and a radiotherapy addition in 53 trials (11.7%). With a median follow-up of 50 months, acute all-grade and grade 3-5 toxicities were reported in 49.6% and 69.4% of studies, respectively. Radiotherapy technique, follow-up and late toxicities were reported in 60.1%, 74%, and 31.1% of studies, respectively. CONCLUSION Phase III randomized controlled trials featured severe limitations, since a third did not report radiotherapy technique, follow-up or late toxicities. The fast-paced technological evolution creates a discrepancy between literature and radiotherapy techniques performed in daily-routine, suggesting that phase III methodology needs to be reinvented.
Collapse
Affiliation(s)
- J C Trone
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - S Espenel
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez;; Laboratory of Cellular and Molecular Radiobiology, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne
| | - A Rehailia-Blanchard
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - E Guillaume
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - N Vial
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - C Rancoule
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez;; Laboratory of Cellular and Molecular Radiobiology, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne
| | - C Rodriguez-Lafrasse
- Laboratory of Cellular and Molecular Radiobiology, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne
| | - M Ben Mrad
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - A El Meddeb Hamrouni
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - E Ollier
- SAINBIOSE U1059, Jean Monnet University, Saint-Etienne
| | - C Chargari
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - E Deutsch
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - A Vallard
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez;; Laboratory of Cellular and Molecular Radiobiology, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne;.
| | - N Magné
- Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez;; Laboratory of Cellular and Molecular Radiobiology, Institut de Physique Nucléaire de Lyon, IPNL, Villeurbanne
| |
Collapse
|
38
|
Espenel S, Guy JB, Wozny AS, Battiston-Montagne P, Rancoule C, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magné N. Évaluation préclinique en modèle tridimensionnel de l’association de l’ABT-199 au cétuximab et aux radiations ionisantes sur les cellules cancéreuses ORL. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Garcia J, Dusserre E, Cheynet V, Bringuier PP, Brengle-Pesce K, Wozny AS, Rodriguez-Lafrasse C, Freyer G, Brevet M, Payen L, Couraud S. Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study. Oncotarget 2017; 8:87980-87996. [PMID: 29152135 PMCID: PMC5675687 DOI: 10.18632/oncotarget.21256] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 06/26/2017] [Indexed: 12/18/2022] Open
Abstract
Non invasive somatic detection assays are suitable for repetitive tumor characterization or for detecting the appearance of somatic resistance during lung cancer. Molecular diagnosis based on circulating free DNA (cfDNA) offers the opportunity to track the genomic evolution of the tumor, and was chosen to assess the molecular profile of several EGFR alterations, including deletions in exon 19 (delEX19), the L858R substitution on exon 21 and the EGFR resistance mutation T790M on exon 20. Our study aimed at determining optimal pre-analytical conditions and EGFR mutation detection assays for analyzing cfDNA using the picoliter-droplet digital polymerase chain reaction (ddPCR) assay. Within the framework of the CIRCAN project set-up at the Lyon University Hospital, plasma samples were collected to establish a pre-analytical and analytical workflow of cfDNA analysis. We evaluated all of the steps from blood sampling to mutation detection output, including shipping conditions (4H versus 24H in EDTA tubes), the reproducibility of cfDNA extraction, the specificity/sensitivity of ddPCR (using external controls), and the comparison of different PCR assays for the detection of the three most important EGFR hotspots, which highlighted the increased sensitivity of our in-house primers/probes. Hence, we have described a new protocol facilitating the molecular detection of somatic mutations in cancer patients from liquid biopsies, improving their diagnosis and introducing a less traumatic monitoring system during tumor progression.
Collapse
Affiliation(s)
- Jessica Garcia
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310, Pierre Bénite, France.,Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Lyon, 69003, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France
| | - Eric Dusserre
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310, Pierre Bénite, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France
| | - Valérie Cheynet
- Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Medical Diagnostic Discovery Department, BioMérieux, 69290 Craponne, France
| | - Pierre Paul Bringuier
- Service d'Anatomie et de Cytologie Pathologiques, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500, Bron, France
| | - Karen Brengle-Pesce
- Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Medical Diagnostic Discovery Department, BioMérieux, 69290 Craponne, France
| | - Anne-Sophie Wozny
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310, Pierre Bénite, France.,Faculté de Pharmacie de Lyon (IPSB), Université de Lyon1, Lyon, 69008, France
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310, Pierre Bénite, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France.,Faculté de Pharmacie de Lyon (IPSB), Université de Lyon1, Lyon, 69008, France
| | - Gilles Freyer
- Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France.,Service d'Oncologie Médicale, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, 69003, France.,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon Sud, Université Lyon 1, 69600, Oullins, France
| | - Marie Brevet
- Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France.,Service d'Anatomie et de Cytologie Pathologiques, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500, Bron, France.,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon Sud, Université Lyon 1, 69600, Oullins, France
| | - Léa Payen
- Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310, Pierre Bénite, France.,Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Lyon, 69003, France.,Laboratoire Commun de Recherche Hospices Civils de Lyon - BioMérieux, Centre Hospitalier Lyon Sud, 69310, Pierre Bénite, France.,Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France.,Faculté de Pharmacie de Lyon (IPSB), Université de Lyon1, Lyon, 69008, France
| | - Sébastien Couraud
- Institut de Cancérologie des Hospices Civils de Lyon, CIRculating CANcer Program (CIRCAN), 69002 Lyon, France.,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon Sud, Université Lyon 1, 69600, Oullins, France.,Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, 69003, France
| |
Collapse
|
40
|
Garcia J, Forestier J, Dusserre E, Rodriguez-Lafrasse C, Cheynet V, Wosny A, Ferraro Peyret C, Brengel-Pesce K, Guillet M, Chauvenet M, Couraud S, Brevet M, Walter T, Payen L. Comparison of performances of three technologies for detection of RAS mutations in cfDNA (NGS strategy, BEAMing assay and ddPCR BioRAD assay). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Wozny AS, Aloy MT, Alphonse G, Magné N, Janier M, Tillement O, Lux F, Beuve M, Rodriguez-Lafrasse C. Gadolinium-based nanoparticles as sensitizing agents to carbon ions in head and neck tumor cells. Nanomedicine 2017; 13:2655-2660. [PMID: 28779947 DOI: 10.1016/j.nano.2017.07.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 06/13/2017] [Accepted: 07/24/2017] [Indexed: 12/31/2022]
Abstract
Hadrontherapy presents the major advantage of improving tumor sterilization while sparing surrounding healthy tissues because of the particular ballistic (Bragg peak) of carbon ions. However, its efficacy is still limited in the most resistant cancers, such as grade III-IV head and neck squamous cell carcinoma (HNSCC), in which the association of carbon ions with gadolinium-based nanoparticles (AGuIX®) could be used as a Trojan horse. We report for the first time the radioenhancing effect of AGuIX® when combined with carbon ion irradiation in human tumor cells. An increase in relative biological effectiveness (1.7) in three HNSCC cell lines (SQ20B, FaDu, and Cal33) was associated with a significant reduction in the radiation dose needed for killing cells. Radiosensitization goes through a higher number of unrepaired DNA double-strand breaks. These results underline the strong potential of AGuIX® in sensitizing aggressive tumors to hadrontherapy and, therefore, improving local control while lowering acute/late toxicity.
Collapse
Affiliation(s)
- Anne-Sophie Wozny
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Oullins cedex, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Marie-Thérèse Aloy
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Oullins cedex, France
| | - Gersende Alphonse
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Oullins cedex, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Nicolas Magné
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Oullins cedex, France; Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, St Priest en Jarez, France
| | - Marc Janier
- Univ Lyon, Université Lyon1, CNRS, LAGEP UMR 5007, IMTHERNAT, Hôpital Edouard Herriot, Lyon, France
| | - Olivier Tillement
- Univ Lyon, Université Lyon 1, Institut Lumière Matière, UMR 5306 CNRS, Villeurbanne cedex, France
| | - François Lux
- Univ Lyon, Université Lyon 1, Institut Lumière Matière, UMR 5306 CNRS, Villeurbanne cedex, France
| | - Michael Beuve
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, PHABIO, Villeurbanne, France
| | - Claire Rodriguez-Lafrasse
- Univ Lyon, Université Lyon 1, UMR CNRS5822/IN2P3, IPNL, PRISME, Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, Oullins cedex, France; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
| |
Collapse
|
42
|
Rodriguez-Lafrasse C, Saintigny Y, Chevalier F, Bernaudin M, Laurent C, Pouzoulet F, Prezado Y, Megnin-Chanet F, François A, Guipaud O, Beuve M, Balosso J. Translational research in radiobiology in the framework of France HADRON national collaboration. Transl Cancer Res 2017. [DOI: 10.21037/tcr.2017.06.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
43
|
Garcia J, Forestier J, Dusserre E, Rodriguez-Lafrasse C, Cheynet V, Wozny AS, Ferraro Peyret C, Brengel-Pesce K, Guillet M, Chauvenet M, Brevet M, Couraud S, Walter T, Payen LF. Comparison of BEAMing assays and competitive approaches in the detection of main alteration of RAS in circulating DNA of non small-cell lung cancer (NSCLC) and metastatic colon cancer. Manuscript 2016. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e23056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e23056 Background: A number of RAS mutations confer resistance to anti-EGFR therapies routinely used in the treatment of colon cancer. The objective of this study was to evaluate the pertinence of analyzing circulating-free plasma DNA (cfDNA) as an indicator of the mutational status of a tumor, in order to use liquid biopsies instead of invasive and painful tumor biopsies during tumor progression. Methods: A cohort of 24 lung and 25 colon cancer patients was constituted in the Hospices Civils of Lyon. Liquid biopsy plasma samples were collected at diagnosis (colon cancer) and during tumor progression (lung cancer) for the purpose of the current study. KRAS and NRAS somatic alterations were quantified using three different technologies: the Droplet Digital polymerase chain reaction (ddPCR) from BioRad, the BEAMing Digital PCR from Sysmex Inostics, and the NGS NextSeq 500 by Illumina with the Accel-Amplicon 56G Oncology Panel from SWIFT BIOSCIENCES. Results: We observed a high level of sensitivity and specificity with the BEAMing technology, which provided us with excellent matches, around 96% and 73%, between solid and liquid biopsies taken at diagnosis (colon cancer) or during tumor progression (lung cancer), respectively. Indeed, when examining cfDNA from patients displaying one of the KRAS or NRAS mutations, 11 of the 13 mutations were confirmed using this technology, whereas only 5-6 matched the initial NGS status, using the two other technologies. The detection threshold was estimated at 1% for samples containing at least 0.8 ngctDNA/µL for the multiplex screening ddPCR from BioRad and for the 56G Oncology Panel from SWIFT BIOSCIENCES. The threshold was lower, at 0.03%, in samples containing only 0.25 ng ctDNA/µL for the BEAMing technology, which includes a PCR pre-amplification step. Conclusions: The advantage of the Illumina NGS technology is the larger coverage of longer gene regions, and thus the detection of more genetic mutations. Finally, the BEAMing technology enabled us to follow the appearance and disappearance of somatic alterations, with a very high level of sensitivity.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Marion Chauvenet
- Hospices Civils De Lyon, Cancer Research Center of Lyon, Claude Bernard University Lyon, Pierre Béninte, France
| | - Marie Brevet
- Centre Hospitalier Universitaire Edouard Herriot, Lyon, France
| | - Sebastien Couraud
- Acute Respiratory Medicine and Thoracic Oncology Department, Lyon Sud Hospital and Lyon University Cancer Institute, Pierre Benite, France
| | - Thomas Walter
- Department of Medical Oncology, Hospices Civils de Lyon, Edouard Herriot Hospital, University of Lyon, Lyon, France
| | | |
Collapse
|
44
|
Méry B, Guy JB, Vallard A, Espenel S, Ardail D, Rodriguez-Lafrasse C, Rancoule C, Magné N. In Vitro Cell Death Determination for Drug Discovery: A Landscape Review of Real Issues. J Cell Death 2017; 10:1179670717691251. [PMID: 28469473 PMCID: PMC5392044 DOI: 10.1177/1179670717691251] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 01/07/2017] [Indexed: 12/19/2022] Open
Abstract
Cell death plays a crucial role for a myriad of physiological processes, and several human diseases such as cancer are characterized by its deregulation. There are many methods available for both quantifying and qualifying the accurate process of cell death which occurs. Choosing the right assay tool is essential to generate meaningful data, provide sufficient information for clinical applications, and understand cell death processes. In vitro cell death assays are important steps in the search for new therapies against cancer as the ultimate goal remains the elaboration of drugs that interfere with specific cell death mechanisms. However, choosing a cell viability or cytotoxicity assay among the many available options is a daunting task. Indeed, cell death can be approached by several viewpoints and require a more holistic approach. This review provides an overview of cell death assays usually used in vitro for assessing cell death so as to elaborate new potential chemotherapeutics and discusses considerations for using each assay.
Collapse
Affiliation(s)
- Benoite Méry
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France
| | - Jean-Baptiste Guy
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France
| | - Alexis Vallard
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Sophie Espenel
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Dominique Ardail
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France
| | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France.,Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France.,Faculté de Médecine Lyon-Sud, Université Claude Bernard Lyon 1, Oullins, France
| | - Chloé Rancoule
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Nicolas Magné
- Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France.,Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon (IPNL), Villeurbanne, France
| |
Collapse
|
45
|
Wozny AS, Alphonse G, Battiston-Montagne P, Simonet S, Poncet D, Testa E, Guy JB, Rancoule C, Magné N, Beuve M, Rodriguez-Lafrasse C. Corrigendum: Influence of Dose Rate on the Cellular Response to Low- and High-LET Radiations. Front Oncol 2017; 6:271. [PMID: 28105406 PMCID: PMC5243835 DOI: 10.3389/fonc.2016.00271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 12/20/2016] [Indexed: 11/13/2022] Open
Abstract
[This corrects the article on p. 58 in vol. 6, PMID: 27014633.].
Collapse
Affiliation(s)
- Anne-Sophie Wozny
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France
| | - Gersende Alphonse
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France
| | | | - Stéphanie Simonet
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1 , Oullins , France
| | - Delphine Poncet
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France
| | | | - Jean-Baptiste Guy
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Departement de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, St-Priest-en-Jarez, France
| | - Chloé Rancoule
- Departement de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth , St-Priest-en-Jarez , France
| | - Nicolas Magné
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Departement de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, St-Priest-en-Jarez, France
| | | | - Claire Rodriguez-Lafrasse
- UMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Univ Lyon, UCBL1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France
| |
Collapse
|
46
|
El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B. EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib. Future Oncol 2017; 13:679-693. [PMID: 28076966 DOI: 10.2217/fon-2016-0357] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
AIM This novel multiparameter Phase I study aimed to optimize doses/dosing schedules of everolimus and sorafenib drug combination, based on modeling/simulation (NCT01932177). PATIENTS & METHODS About 26 patients with solid tumors were treated in four different dosing schedules. Everolimus once daily + sorafenib twice daily were given continuously in arms A and B, and intermittently in arms C (alternating every other week) and D (everolimus continuous and sorafenib 3 days on/4 days off). RESULTS Continuous schedules exhibited higher toxicity risks than intermittent schedules (64.1 vs 35.9%; p < 0.0001), and trends for lower disease control rates (80 vs 100%). No significant pharmacokinetic interaction was identified. CONCLUSION Feasibility of EVESOR trial is demonstrated. Intermittent schedules might provide better tolerance and efficacy than continuous schedules.
Collapse
Affiliation(s)
- Mévidette El-Madani
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,National Research Centre, Pharmacology Department, Cairo, Egypt
| | - Olivier Colomban
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France
| | - Michel Tod
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France
| | - Denis Maillet
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Julien Peron
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Claire Rodriguez-Lafrasse
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,Biochemistry & molecular biology department; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Osama A Badary
- Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Pierre-Jean Valette
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,Radiology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Thibaud Lefort
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,Radiology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | | | | | - Ebtehal El-Demerdash
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Juliette Hommel-Fontaine
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,Pathology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Jerome Guitton
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France
| | - Marie-Claude Gagnieu
- Biochemistry & molecular biology department; Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | | | - Catherine Barrois
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Gilles Freyer
- Faculté de Médecine Lyon-Sud, Univ Lyon, Université de Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France.,Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France
| | - Benoit You
- Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, Lyon, France
| |
Collapse
|
47
|
Rancoule C, Vallard A, Espenel S, Guy JB, Xia Y, El Meddeb Hamrouni A, Rodriguez-Lafrasse C, Chargari C, Deutsch E, Magné N. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncol 2016; 62:153-162. [DOI: 10.1016/j.oraloncology.2016.09.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 07/26/2016] [Accepted: 09/04/2016] [Indexed: 12/25/2022]
|
48
|
Guy J, Méry B, Rancoule C, Vallard A, Espenel S, Wozny A, Simonet S, Bernard D, Ardail D, Beuve M, Alphonse G, Rodriguez-Lafrasse C, Magné N. HER Family Blockade in Head and Neck Squamous Cell Carcinoma: Couple Therapy Efficacy of Cetuximab and Pertuzumab Combined With Photon Irradiation. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Guy J, Méry B, Rancoule C, Vallard A, Espenel S, Wozny A, Ardail D, Alphonse G, Rodriguez-Lafrasse C, Magné N. Ciblage de la famille HER dans les cancers ORL : efficacité biologique de l’association de cétuximab et de pertuzumab combinée à l’irradiation photonique. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
50
|
Vallard A, Espenel S, Guy JB, Diao P, Xia Y, El Meddeb Hamrouni A, Ben Mrad M, Falk AT, Rodriguez-Lafrasse C, Rancoule C, Magné N. Targeting stem cells by radiation: From the biological angle to clinical aspects. World J Stem Cells 2016; 8:243-250. [PMID: 27621758 PMCID: PMC4999651 DOI: 10.4252/wjsc.v8.i8.243] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 06/18/2016] [Accepted: 07/13/2016] [Indexed: 02/06/2023] Open
Abstract
Radiotherapy is a cornerstone of anticancer treatment. However in spite of technical evolutions, important rates of failure and of toxicity are still reported. Although numerous pre-clinical data have been published, we address the subject of radiotherapy-stem cells interaction from the clinical efficacy and toxicity perspective. On one side, cancer stem cells (CSCs) have been recently evidenced in most of solid tumor primary locations and are thought to drive radio-resistance phenomena. It is particularly suggested in glioblastoma, where CSCs were showed to be housed in the subventricular zone (SVZ). In recent retrospective studies, the radiation dose to SVZ was identified as an independent factor significantly influencing overall survival. On the other side, healthy tissue stem cells radio-destruction has been recently suggested to cause two of the most quality of life-impacting side effects of radiotherapy, namely memory disorders after brain radiotherapy, and xerostomia after head and neck radiotherapy. Recent publications studying the impact of a radiation dose decrease on healthy brain and salivary stem cells niches suggested significantly reduced long term toxicities. Stem cells comprehension should be a high priority for radiation oncologists, as this particular cell population seems able to widely modulate the efficacy/toxicity ratio of radiotherapy in real life patients.
Collapse
|